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The present study investigated pharmacological properties of Capsicum frutescens-
derived capsaicin, including its analgesic, anti-inflammatory and coagulatory 
properties. The effects of capsaicin on gastrointestinal and myocardial muscles, as 
well as on myocardial ischaemic-reperfusion, were also investigated.  
 
Capsaicin pre-treatment in neonatal rats has been found to abolish the development of 
thermal hyperalgesia produced in a model of neuropathic pain in rats (Toth-Kasa et 
al., 1986). In addition, capsaicin sensitivity has been found to be dependent on 
continued presence of nerve growth factor (NGF), whose concentration increases in 
inflamed tissues (Bevan and Winter, 1995). By stimulating the release of excitatory 
amino acids (EAA); such as glutamate and neuropeptides [(CGRP, neurokinin A 
(NKA) and Substance P (SP)] from both the peripheral and central terminals of 
sensory neurones by two mechanisms (Kroll et al., 1990; Del Bianco et al., 1991; Lou 
et al., 1992; 1994; Woolf et al., 1994); capsaicin has been shown to produce a longer-
term inhibitory effect. This is one likely mechanism for capsaicin analgesic and anti-
inflammatory actions (Bleakman et al., 1990).  
 
Within the gastro-intestinal tract, SP and NKA are involved in the physiological 
control of several digestive functions, such as motility, fluid and electrolyte secretion, 
blood flow, and tissue homeostasis (Otsuka, 1993; Holzer et al., 1997). Consistent 
with this finding, upsurge of SP in irritable bowel syndrome (IBD) was confirmed by 
Mantyh et al, (1988). Pre-treatment of rats with either capsaicin or NK-1R antagonists 
dramatically reduced fluid secretion, mucosal permeability, and intestinal 
inflammation in animal models of acute and chronic inflammation (McCafferty et al, 
1994; Pothoulakis et al., 1994). 
 
Capsaicin can modulate endocrine and paracrine activities, immune responses, as well 
as gastro-intestinal and cardiovascular functions. Moreover, up-regulation of 
Substance P receptors was found to be associated with chronic inflammatory 
conditions (De et al., 1990). Stimulation of transient receptor potential vanilloid 1 
also results in the activation of nociceptive and neurogenic inflammatory responses 
(Rigoni et al., 2003).   
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The pharmacodynamic effects of capsaicin on the cardiovascular system remain 
elusive. Some actions of capsaicin on the heart were attributed to an interaction at K
+
 
channels (Castle, 1992), or liberation of neuropeptides, most notably calcitonin-gene-
related-peptide (CGRP) from the vanilloid-sensitive innervation of the heart (Franco-
Cereceda et al., 1988; 1991). The possibility of a direct effect of capsaicin on the heart 
via a cardiac vanilloid receptor (VR), or through interaction of vanilloid receptors 
with purinergic receptors, and subsequent release of nitric oxide (NO), leading to 
vasodilatation were considered. Evidence abound in the literature that Ca
2+ 
ions are 
released through 1, 4, 5 inositol phosphatase by the release of phospholipase C, or 
through interaction of the vanilloid receptors with cannabinoids. In an earlier study, 
Jaiarj et al. (1998) found that capsaicin acting on the heat-sensitive vanilloid 
receptors, had thrombolytic effects. Though weak evidence, Jaiarj et al. (1998) 
observed that individuals who consume large amounts of Capsicum have lower 
incidence of thromboembolism. 
 
Following ethical approval, the study reported in this thesis was conducted in phases. 
Identification of Capsicum frutescens (facilitated by a botanist in the Department of 
Botany, Westville campus of the University of KwaZulu Natal). Chromatographic 
extraction of capsaicin from Capsicum frutescens was followed by Nuclear Magnetic 
Resonance (NMR) analysis of the extract. Animal studies were conducted using 
capsaicin extract (CFE) and/or a reference capsaicin (CPF), using „hot plate‟ and 
„acetic acid‟ test methods to investigate the role of capsaicin on analgesia. Fresh egg 
albumin-induced inflammation was used to investigate the role of capsaicin in 
inflammation, following pre-treatment with CFE and CPF. Concentraton-response 
curves of increasing concentrations of capsaicin, acetylcholine and other agonist 
drugs with specific antagonists on strips of chick oesophagus, guinea-pig ileum, and 
rabbit duodenum were constructed following investigations on gastrointestinal (GIT) 
smooth muscles. The effect of capsaicin on coagulation was assessed by measuring 
international normalized ratio (INR) of animals that were exposed to different 
concentrations of capsaicin (CFE and CPF). Furthermore, parallel control studies 
were conducted in each of these investigations using distilled water or saline as 
placebo-control or specific-prototype agonists‟ negative-control. Cardiovascular 
investigations included studies on the effects of capsaicin on the heart rate, inotropy, 
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coronary perfusion pressure, and ischaemic-reperfusion injury, using Langendorf‟s rat 
heart models. 
 
Collated data were triangulated by manual hand-written and PowerLab data 
acquisition, or computerised capture. Statistical analysis were performed by either one 
or two of the following: Student‟s t-test, ANOVA (repeated or single–use modes), 
facilitated and confirmed by Graph Pad Prism, Microsoft Excel or CPSS software(s). 
 
Reproducibility and relevance to the stated objectives of the various studies were 
confirmed by assessing which of the Null or Alternative hypothesis is validated by the 
results from the test. 
 
Treatment with CFE or CPF at all doses significantly (p<0.01) increased MRT. 
By comparison with control, writhing responses to acetic acid were significantly 
reduced following pre-treatment with various doses of CFE or CPF.  The results 
in both parallel groups of CFE and CPF in the hot plate and acetic acid tests had 
Pearson correlation of one (1). 
 
Compared to the diclofenac (DIC) group, the degree of inhibition of paw 
oedema by CFE and CPF was statistically significant (P<0.05-0.001), best in the 
first 4 hours of treatment.  
 
The results of the in vitro laboratory animal study indicate that relatively low 
concentration of CPF (20 or 40 g) produced significant (p0.05), concentration-
related inhibitions of acetylcholine (0.1-5 g)-induced contractions of the chick 
isolated oesophagus, guinea-pig isolated ileum and rabbit isolated duodenum. 
Biphasic effects, which were noticed at low concentrations, consisted of initial brief 
contractions, followed by longer-lasting relaxations and reductions of the contractile 
amplitudes of the muscle preparations. Percentage inhibitions of the smooth muscle 





The difference means of INR between the treatment groups was statistically 
significant (P<0.05), showing INR of 1 ± 0.1, 1.4 ± 0.1 and 2.0 ± 0.3, respectively, for 
the treatment groups of CFE, 2.5, 5.0, 10 mg/kg, respectively. 
The results obtained from cardiac muscle experiments showed biphasic effects with 
concentration-dependent increases in the heart rate from a capsaicin dose of 0.05 
µg/ml up to a dose of 0.3 µg/ml (at P<0.001), and decrease in the mean heart rate of 
the Witstar rats‟ hearts from a dose of 0.3- 1 µg/ml (at P< 0.001). The slope of the left 
ventricular diastolic pressures per unit change in time (dp/dt) showed a dose-
dependent reduction in the left ventricular contraction when treated with a 
concentration range of 0.05-1 ug/ml (at P < 0.001). Unlike earlier studies, the bulk of 
the evidence from this study showed that capsaicin extract may not be the best agent 
to protect the heart against ischaemia-reperfusion injury.  
In conclusion, the results of the present study indicate that capsaicin has analgesic, 
anti-inflammatory, and anti-coagulatory effects. The effects of capsaicin on GIT 
smooth muscles and cardiac muscles are biphasic, with stimulatory and inhibitory 
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CHAPTER 1 
 
INTRODUCTION and BACKGROUND INFORMATION 
 
SUMMARY: This chapter gives an overview of the aims and objectives of the 
study, and lays the ethical, phytochemical and biochemical foundation for the use of 





The last half of the 20
th
 century witnessed an upsurge in the knowledge of 
neurotransmitters. It made a significant contribution and advancement in pain 
management. It was discovered that the pain pathway is more complex than a 
common ascending afferent pathway whose messages were processed by a central 
mechanism at a specific pain center with an efferent effector mechanism through a 
descending pathway. In the same vein, both the autonomic and the neuro-humoral 
mechanisms are involved in pain mechanisms. The complex mechanisms of 
transmission and transduction of pain also involve several neurotransmitters, such as 
catecholamines, acetylcholine, vasoactive intestinal polypeptide (VIP), neuropeptide 
Y (NPY), cholecystokinin, 5-hydroxtryptamine, neurotensin, tachykinin, bradykinin 
and several others (Caterina and Julius, 2001). Specific genes called oncogenes- c-
fos and v-fos are implicated in the memory of pain (Wallace, 1997). Recently, the 
non-adrenergic and non-cholinergic (NANC) neurotransmitters were discovered in 
the afferent and efferent pain pathways. Also, the peripheral and central 
mechanisms of endorphins, cyclo-oxygenase and the leukotrienes, are becoming 
evident. 
 
However, the understanding of hyperalgesia, allodynia, and phantom or stump pain 
became obvious and evident with the discovery of N-methyldeamine aspartate 
(NMDA) receptors. Modulation of these receptors by specific antagonists has 
prevented the excitatory amino acids from gaining access to producing pain and 
neuronal injury (Marinelli, 2003). Such knowledge of the existence of non-specific 
excitatory and inhibitory systems in the central nervous system (CNS) has 
contributed to the development and use of co-analgesics and secondary analgesics in 
the relief of acute and chronic pain (Dray, 1992). 
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Although the 'gate control' theory of pain (Melzak and Wall, 1965) facilitated a 
better understanding of the perception and processing of pain by small and larger 
nociceptive fibers; Dickenson (2002) in an editorial affirmed that the latter theory 
had stood the test of time. Also, it was discovered that Substance P was released as 
the neurotransmitter at the primary afferent terminals of the dorsal root ganglion 
(DRG) (Caterina and Julius, 2001; Winter, et. al (1995)). Unfortunately, the lack of 
specific Substance P antagonists was frustrating. The centenarian study on the 
physiological effects of oily extracts from red peppers showed that capsaicin is the 
active Substance P antagonist (Capsaicin Study Group, 1999). It acts by depleting 
Substance P from its vesicles at the primary afferent neurons, following an initial 
increase in its concentration (Bevan, 1990). Ultimately, it reduces the duration and 
biological action of Substance P by tachyphylaxis.  
 
Current research reports have shown that capsaicin exhibits various potent 
biological activities following oral or topical administration (Capsaicin Study 
Group, 1999).  These include initial hyperalgesia (Coderre et al., 1991; Davis et al., 
2000) analgesia, dyspepsia, anti-inflammatory (Attal, 2001); anti-pyretic and anti-
coagulatory activities (Jaiarj et al., 1998; De Smet, 2002). Furthermore, capsaicin 
can modulate endocrine and paracrine activities, immune responses, gastro-
intestinal, and cardiovascular functions (Jaiarj et al., 1998). In addition, capsaicin 
has proved to be very useful in intractable pain of diabetic neuropathy (Bernstein et 
al., 1989); cluster headache (Fusco, et.al. 1991; herpetic neuralgia and trigeminal 
neuralgia (Campbell et al., 1993; Epstein and Marcoe, 1994). 
 
Although red chilli peppers are cosmopolitan and various species are cultivated in 
southern Africa, research work in this field is limited locally. Apparently, imported 
capsaicin is very expensive. To this end, this study will advance the course of 
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1.2.   RESEARCH OBJECTIVES    
 
The main aim of this study was to determine the pharmacodynamic effects of 
capsaicin from South African Capsicum frutescens Linn. (Family: Solanaceae). 
 
The main objectives of this study were to: 
 
  (i).     Evaluate the analgesic properties of capsaicin; 
     (ii).    Determine the anti-inflammatory effects of capsaicin; 
     (iii).   Determine if capsaicin has effects on coagulation; 
     (iv).   Assess the effects of capsaicin on the cardiovascular system; and 
     (v).   Assess the effects of capsaicin on gastro-intestinal smooth muscles.  
 
1.3.      HYPOTHESIS           
 
1.3.1.   NULL HYPOTHESIS 
 
Capsaicin extracted from local South African Capsicum has no analgesic, anti-
inflammatory and anti-coagulant effects. It also lacks effects on the gastrointestinal 
and cardiovascular systems. 
 
1.3.2.   ALTERNATIVE NULL HYPOTHESIS 
 
Capsaicin extracted from local South African Capsicum has analgesic, anti-
inflammatory and anti-coagulant effects. It also has effects on the gastrointestinal 









 4  
1.4.       ORGANIZATION OF THE STUDY 
 
There were three phases of this study. In the first phase, a study protocol and 
theoretical framework was laid down. Ethical approval was then obtained from the 
University's Animal Ethics Committee. The second phase involved identification of 
Capsicum spp and extraction of capsaicin. In the third phase, animal experiments 
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SUMMARY: This chapter gives an overview of the natural history of Capsicum 
frutescens and the climatic conditions favouring its growth. In addition, the receptor 
pharmacology of capsaicin and its role in pain pathways are discussed.  
 
2.1.1. EVOLUTION and REVOLUTION OF PHYTOCHEMICALS 
 
During the past century, medical science has improved with advancements in 
technology. However, the most effective tools for disease eradication may be found 
in edible fruits and vegetables. Phytochemicals, natually occurring biochemicals 
that give plants their colour, flavour, smell and texture, may help prevent diseases 
that are responsible for over 50% of all deaths annually in the United States. In 
1900, the top killer diseases responsible for 31% of all deaths were found to be 
pneumonia/influenza, tuberculosis, and diarrhoea/gastroenteritis (Taylor and Field, 
1997; Stucky, et.al., 1998). However, mortality reduced significantly consequent 
upon the improvement in public health, nutrition and sanitation. For example, 
influenza and pneumonia had a 70% drop in mortality from 12% to 3.6% per year. 
Although mortality had increased for stroke, cancer and heart diseases, there is 
increasing evidence that the exceptionally high death rates from the last three causes 
are preventable, and can be lowered with changes in diet, life-style, and 
environment. Phytochemical revolution took a positive turn in the 1970s onward, 
with the development of many laboratories that were involved in the production of 
bioactive nutriceuticals such as beta-carotene, omega-6 and other vitamins, with 
positive health deriving values. Capsaicin is a chilli pepper-derived spice. Apart 
from its spicy and flavourant properties, it has been found to be a digestive aid, a 





2.1.2     CAPSICUM -THE NATURAL HISTORY AND SCIENCE 
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'Capsicum' is synonymous with Chillies; Cayenne pepper; Red peppers; Spanish 
pepper; Mirch (Hindi); Capsicum fruits; Fructus capsci. Capsicum consists of the 
dried, ripe fruits of Capsicum frutescens Linn. (African Chillies) or, of Capsicum 
annuum Linn. Var conoides (Tabasco pepper), or of Capsicum annuum var, longium 
(Lousiana Long pepper), or a hybrid between the Honka variety of Japanese 
capsicum and the old Louisiana Sport Capsicum known as Loisiana Sport pepper. 
They all belong to the Family Solanaceae (Sofowora, 1993; Watt and Breyer-
Brandwijk, 1962). 
 
Capsicum is native to America, and the early Spanish explorers brought it to the 
„New World‟. It is cultivated in tropical regions of India, Nigeria, Japan, Southern 
Europe, Mexico, other African countries and Sri Lanka. 
 
Capsicum is 5-12 cm long, 2-4 cm wide; and could be globular, cylindrical, oval, or 
oblong in shape.  It has a shrivelled shape and could be orange, green, yellow or red 
in colour, with a prominent and bent pedicle. Internally, the fruits are divided into 
two halves by a membranous dissepiment to which the seeds are attached. Capsicum 
has a characteristic odour, and an intense pungent taste.  
 
                  A T Jolayemi/2003                                                               
Figure 2.1. Different species of Capsicum and the finished products (spices) bottled.  
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Although Capsicum can withstand tropical heat, it requires 3 months rainfall, and 
thrives best in wet climate. The fruit yield is directly proportional to the manure of 
the cultivated farm. 
 
The fruits are picked as they become fully ripe. The unripe fruits fade upon drying. 
The fruits are dried in sun and graded by colour. The quality of the fruit is in part 
determined by its colour, and they are occasionally oiled to give glossiness to their 
pericarps.  
 
2.1.3.    CHEMISTRY OF CAPSICUM 
 
Capsicum contains fixed oils (0.1-1%). They are oleoresin, carotenoids, capsacutin, 
capsico (a volatile alkaloid), volatile oil (1.5%) and ascorbic acid (0.2%). The resin 
contains an extremely pungent principle, capsaicin, (decyclenic vinillylamide) 
(about 0.5%). Capsaicin retains its characteristic pungency in a dilution of 1 part in 
10 million parts with water. The maximum concentration of capsaicin is in the inner 
walls. Its pungency is unaffected by alkalis, but it is destroyed by oxidising agents. 
Capsanthin is the main carotenoid of red fruits. It also occurs as monoester and 
diester along with cryptocapsin. Other carotenoids include zeaxanthin, lutein, 
-carotenes, and few xanthophylls. The carbohydrates 
reported in chillies are fructose, galactose, sucrose, fructosyl-sucrose, planteose, 
planteobiose, etc. Tocopherol (vitamin E) is present in trace amounts-~2.4 mg/100g.  
 
The pungent compounds of Capsicum frutescens are capsaicin (69%), 
dihydrocapsaicin (22%), norhihydrocapsaicin (7%), homocapsaicin (1%) and 
homodihydrocpsaicin (1%). The aromatic portion of capsaicin is derived from 
phenylalanine through frulic acid and vanillin. This aldehyde is a substrate for 
transamination to give vanilylalamine. The acid portion of the amide structure is of 
polyketide origin, with a branched-chain fatty acyl-CoA, which is produced by 
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2.1.4.   MEASUREMENT OF PUNGENCY AND POTENCY OF  
               CAPSICUM SPECIES 
 
In 1912, Wilbur Scoville developed a dilution taste method, called “Scoville 
Organoleptic Test”, to measure the heat level of a chilli pepper.  It consists of 
blended pure grounded chillies with sugar-sweetened solution, following which a 
panel of testers then sipped the concoctions. He increasingly diluted the 
concentrations until they reached the point at which the liquid no longer burned the 
mouth. A number was then assigned to each chilli based on how much it needed to 
be diluted before one could taste no heat.  
 
The pungency of chilli pepper is measured in multiples of 100 units from the bell 
pepper (green or yellow Capsicum annum) at zero scoville units to the incendiary 
Habanero at 300,000 Scoville units. One part of chilli “heat” per 1,000,000 drops of 
water, rates as only 1.5 Scoville units. The substance that makes chilli so hot and 
therefore, so enjoyable, is capsaicin. Pure capsaicin rates over 150,000,000 Scoville 
units. Red Savina Habanero is much hotter than the normal Habenero with 
„Guinness Book of Records‟ of 577,000 Scoville units while the Trinidad scorpion 
Moruga tests over 2 million Scoville units.  
 
The validity and accuracy of the Scoville Organoleptic Test (SOT) have been 
widely criticised. The Gillet method adopted by the American Spice Trade 
Association and the International Organisation for Standardisation is a modified 
version of the SOT. Although very costly, the High Performance Liquid 
Chromatography is the most objective analysis for obtaining the purest form of 
capsaicin.  
 
Capsaicin (N-Vanillyl-8-methyl-6- (E)-noneamide) is the most pungent of all the 
groups of compounds called “capsinoids” that can be isolated from chilli peppers. It 
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2.1.5. USES OF CAPSAICIN 
 
Capsaicin has been used externally as a stimulant, counter-irritant, rubefacient, in 
sore throat and scarlatina, hoarseness, dyspepsia, and yellow fever. Capsaicin is 
used as a carminative, stomachic, for atonic dyspepsia and flatulence. In the form of 
ointment, plaster, medicated wool, it is used for the relief of rheumatism, lumbago. 
The effect of capsaicin results from the activation of the vanilloid receptors, which 
ultimately activates the C fibre nerve endings, and thereby depletes the dorsal 




2.2.    PHYSIOLOGY AND PHARMACOLOGY OF PAIN 
 
Pain is perceived through both peripheral and central mechanisms. Peripheral 
mechanisms typically involve the nociceptors, while central mechanisms involve 
the process of central sensitization.  
 
2.2.1.    PAIN PATHWAYS   
 
The pain pathways consist of the nociceptors, primary afferent neurons which 
transmit messages through the ascending nociceptive tracts, pain discriminating 
elements in the higher centres in the central nervous system (CNS), and an effector 
mechanism through the descending tracts. The nociceptors are free nerve endings 
which can be divided, using three criteria according to the degree of myelination, 
into A- - -
response (into mechanical, chemical and thermal nociceptors), and the response 
characteristics. Some of the nociceptors have mixed functions, for example, certain 
C and delta fibers which act as mechano-thermal receptors. There are also some C 
to heat 
and cold, and to a variety of chemicals, such as bradykinin, hydrogen ions, 
serotonin, histamine, arachidonic acid and prostacyclin (Brenner, 2002).  Using 
specific pain producing molecules, three different nociceptive fibers were found to 
be implicated in neuropathic pain; type I, type II and type III neurons. Type I 
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neurons are polymodal C-fibers, and they drive the NK 1-receptor mechanisms in 
spinal pain transmission. Type II neurons are also polymodal and they drive the 
NMDA receptor-mechanisms, while type III neurons are capsaicin insensitive, and 
possibly drive or markedly enhance the NMDA-receptor mechanisms (Decosterd 
and Woolf, 2002). Such pain transmission switch mechanisms are clearly consistent 
with clinical effectiveness, including less sensitivity to morphine and more 
sensitivity to NMDA-antagonists. 
 
 The neural impulses which originate from the nociceptors relay through the 
primary afferent nerves (PAN), to the spinal cord, or via the cranial nerves to the 
brain stem; for those impulses which originate from the head and neck.  The cell 
bodies of these ganglia are located in the dorsal root ganglia, or the respective cell 
bodies in the cases of cranial nerves V, VIII, IX, and X. By means of complex 
synapses, messages are relayed to ascending pathways.  
 
 The ascending pathways consist of 10 laminae into which numerous types of cell 
bodies and dendrites converge. For example, the majority of nociceptors converge 
on laminae I (the marginal zone), laminae II (substantia gelatinosa) and lamina V in 
the dorsal horn. It is from these laminae that the second order neurons, which later 
re-organize into tracts respectively called “spinothalamic, spinohypothalamic” 
tracts, arise. The cranial nerves have their respective tract associations (Brenner, 
2002; Decosterd and Woolf, 2002). The integration and higher processing of pain 
consists of discriminative component, affective component, memory, as well as the 
motor control of pain, which are effected in the thalamus, hypothalamus, limbic 
system, cerebral cortex and the cingulate cortex, respectively. 
 
2.2.2.     PHARMACOLOGY OF PAIN RECEPTORS 
 
There are several biochemical mediators (and neurotransmitters), which are 
involved in pain transmission and perception. Peripherally, the most important of 
these amines are the cyclo-oxegenase agonists and the leukotrienes. Others are 
catecholamines, acetylcholine, vasoactive intestinal polypeptides (VIP), 
neuropeptides Y (NPY), cholecystokinin, 5-hydroxytryptamine, neurotensin, 
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tachykinin, and bradykinins (Miao and Levine, 1999; Nagy, 1985). The opioid 
receptors act both centrally and peripherally. In addition, the central cyclo-
oxygenase action has been found with acetaminophen (Sinoff and Hart, 1993). 
             
Centrally-acting neuromediators, can be classified into „excitatory,‟ and „inhibitory,‟ 
neuromediators. Glutamate and aspartate are the examples of excitatory amino acids 
acting as neurotransmitters centrally, while Substance P (SP), calcitonin gene-
related peptide (CGRP) (Lou, et al., 1991), and growth factors (e.g., brain-derived-
neurotrophic factors) are other examples. Inhibitory neuromediators include 
-endorphins. Others are gamma-
-adrenergic agonists (Nakamura and 
Shiomi, 1999). Conversely, any agent acting on these receptors and neuromediators 
have the ability to modulate pain. The aberration of inflammatory and neuropathic 
enhancement of pain perception as seen in allodynia (painful touch) and 
hyperalgesia are due to increased release of SP from substantia gelatinosa. This 
phenomenon is called 'peripheral sensitization'.  
 
  
Figure 2.2. Multi-receptor and multi-synaptic pain mechanisms (Adapted from 
Bevan, S. Trends in Pharmacological sciences, 1990). 
 
2.2.3   SUPRANUCLEAR PAIN RECEPTOR MODULATION   
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The memory of pain, neural plasticity, wide dynamic range activity and the winding 
phenomenon are enhanced by N-methyl-D-aspartate receptor through an early 
expression of genetic coding through c-fos and v-fos oncogens (Woolf and Salter, 
2000; Wallace, 1997; Chiang, et al., 1997 and 1999). This neural plasticity leads to 
the phenomenon of central sensitization as typified by stump and phantom pain. 
Both hyperalgesia and allodynia, which are known side effects of capsaicin (Liu, 
et.al. 1996), are results of peripheral and central sensitization. In addition, the 
repetitive C fiber stimulation produces the winding-up phenomenon. 
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Figure 2.4 a & b. Injury leads to nociception, transduction, receptor modification, 
unco-ordinated spouting, and growth of injured axons and ectopic epileptic firing of 




2.2.4.           HIGHER CEREBRAL FUNCTION IN PAIN 
 
 Although the hypothalamus receives an enormous amount of stimuli, it is devoid of 
the ability to discriminate, since it is not somatotopically organized. It is also not 
able to localise pain. However, discrimination and localisation are possible by the 
third order neurons connecting to the prefrontal gyrus in the cerebral cortex. This is 
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2.2.5.             PAIN ASSOCIATED AREAS IN THE BRAIN  






















Figure 2.6. Ascending and descending pathways (Adapted from Sorkin, L.S. 1997).  
Affect and mood contribute a great deal to pain perception. This is due to the 
connection of the limbic system, the cingulate cortex, and the cerebral cortex to 
the spinothalamic tract, the thalamus and the reticular formation. The ascending 
order is not alone in pain modulation. There is enough evidence to suggest that the 
descending tracts have a role in the modulation of pain (Decosterd and Woolf, 
2002). In the late 1960s, it was observed that neurons in the dorsal horn of 
decerebrate animals are more responsive to painful stimuli when the spinal cord is 
blocked (Wall and Melzack, cited by Stojanovic, 2002). Also in the late 1980s, 
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electrical stimulation of the periaqueductal gyrus was found to produce profound 
relief of pain in animals (Wallace, 1997). These studies provided scientific basis 
for stimulation-produced analgesia. In addition, further studies showed that 
instillation of small doses of morphine in the regions such as periaqueductal 
system (PAG) produced significant analgesia. 
 
2.2.6.      SUMMARY OF PAIN MECHANISMS 
 
Pain is sensed by nociceptors located in the sensory nerve endings. Messages are 
relayed through complex multisynaptic afferents to the dorsal column by means of 
transmission and transduction of chemical messages which are relayed via the spinal 
mechanisms and processed for appropriate supranuclear interpretation. Finally, the 
motor effector organs are facilitated to respond according to the type of pain 
(Vasko, 1995; Shipton, 1999). 
 
 
2.3.   PHYSOLOGY AND PHARMACOLOGY OF SUBSTANCE P 
                                       
Substance P is the active neurotransmitter that is released at the primary nerve 
endings of primary afferent neurons (PAN). It is usually synthesized at the 
substantia gelatinosa of the dorsal horn.  On release from PAN, Substance P from 
the dorsal horn of the spinal cord exhibits systemic actions.  For example, the 
expression of Substance P and vanilloid receptor (VR1) were found in the 
trigeminal sensory neurons projecting from PAN to the nasal mucosa in the mouse 
(Dinh et al., 2003, Liu, et al. 2001).  The release of both Substance P and 
neurokinin A (NKA) from PAN to various stimuli induced by capsaicin (vanilloid) 
receptor (VR1) results in potent pro-inflammatory effects on the airways (Toh, et 
al., 1955; Davis et al., 2000). 
 
Expression of Substance P was found to correlate with the severity of diarrhoea in 
cryptosporidosis from the result in electrogenic chloride anion secretion (Ritta and 
Dinh, 1993; Robinson, et al. 2003. Yang et al. (2003) found three kinds of current 
in response to Substance P in bullfrog dorsal root ganglion neurons. They are 
either G-protein coupled channel, slow activating I (SP); or directly opened 
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channel, fast activating I (SP); or both, moderately activating I (SP). All the three 
were inwardly directed currents with the ionic mechanism underlying slow 
activating I (SP) deduced as closure of K
+
 channels. The fast-activating channel is 
due to the opening of sodium channels. These correlate with the three subtypes of 
SP receptor, immunoreactive interneurons described in the rat basolateral 
amygdala (Leibosohn, 1992). Furthermore, the secretion of HCO
-
3 through 
secretin was abolished by Substance P (Hajos et al., 1986; Gronroos et al., 1997; 
Leis et al., 2003). 
 
Other systems affected by Substance P include the cardiovascular system. Low 
dose systemic administration of Substance P caused hypertension and tachycardia, 
while unilateral or bilateral injections into the rat's nucleus tractus solitari caused 
slow increase in blood pressure and heart rate, which peaked in 1.5-5 minutes after 
injection, and lasted for 20-30 minutes. These effects are vagal-mediated (Abdala 
et al., 2003; Jaiarj et al., 1998). 
 
Furthermore, the swellings that typically accompany complex regional pain 
syndrome have been found to be due to extravasation of Substance P-induced 
protein (Levita et al., 2003; Leis et al., 2003).         
 
2.4       HOW AND WHERE CAPSAICIN ACTS? 
 
Capsaicin is the main pungent ingredient in „hot‟ chilli peppers, and elicits a 
burning pain by selectively activating sensory neurons that convey information 
about noxious stimuli to the central nervous system (Naggy, 1995; Rang and Urban, 
1995). However, capsaicin-induced ion refluxes increase cyclic GMP and not cyclic 
AMP (Wood, et. al., capsaicin has selective action on unmyelinated C-fibers and 
thinly-myelinated A primary sensory neurons (Wood, et al., 1989). 
 
Capsaicin-sensitive fibers are polymodal nociceptors, which respond to a variety of 
sensory stimuli, including noxious pressure, heat and chemical irritants. They are 
the most abundant class of nociceptive fibres. When stimulated by capsaicin, 
nociceptive neurones release glutamate, which is a rapidly-acting central 
neurotransmitter. In addition, these nociceptive fibers also express neuropeptides, 
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such as calcitonin-gene-related-peptide (CGRP), Substance P, nerokinin A and 
somatostantin, which, on release to the spinal cord, leads to intense stimulation. The 
tachykinins (e.g., Substance P and neurokinin A) and excitatory amino acids 
(EAAs) (e.g., glutamate), co-operate and are thought to increase synaptic activation 
of dorsal horn neurones via EAA receptors. Noxious stimulation acting on 
peripheral nervous system results in a long-term increase in spinal excitability, 
which results in the central mechanisms of allodynia and hyperalgesia. Most of the 
neuropeptides synthesized in the dorsal root ganglion are exported peripherally and 
not centrally, to facilitate neurogenic inflammation.  Capsaicin pre-treatment in 
neonatal rats has been found to abolish the development of thermal hyperalgesia 
produced in a model of neuropathic pain in rats (Toth-Kasa et al., 1986; Docherty, 
et al., 1991). 
 
An initial local application of capsaicin is algesic (Kinnman, et al., 1997). However, 
its repeated application leads to desensitization, and its high concentration 
eventually blocks conduction of the C-fibres. This results in long-lasting sensory 
deficits. These properties give a logical basis for the use of capsaicin in treating 
pains that arise from cluster headache, complex regional pain syndrome, post-
mastectomy pain, post herpetic neuralgia, and diabetic neuropathy (Sicuteri, et al., 
1989; Karlstein and Gordh, 1997; Scheffler, et al. 1991).   
 
2.5.          INTERACTION OF SUBSTANCE P, CAPSAICIN,  
         VANILLOID RECEPTORS AND OTHER RECEPTORS 
 
2.5.1.       CAPSAICIN RECEPTOR 
 
Caterina et al., (1997) used expression-cloning strategy based on calcium influx to 
isolate a functional cDNA encoding of a capsaicin receptor from sensory neurons. 
Capsaicin receptor is a non-selective cation channel, that is structurally identified 
with members of the Transient-Receptor-Potential V1 (TRPV1) family of ion 
channels (Caterina, et al. 2001; Cesare, et al. 1999; Chaundry, et.al., 2001). The 
cloned-capsaicin receptor is also activated by increases in temperature in the 
noxious range, which suggests that it acts as a transducer of painful thermal stimuli 
in vivo. 
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In all, twenty-eight (28) mammalian Transient Receptor Potential (TRP) cation 
channels have been identified and re-grouped into six subfamilies (Vriens J, 
Appendino G, Nilius B; 2008).  These include, TRPC (“Canonical”), TRPV 
(vanilloid”), TRPM (“Melastatin”), TRPP (“Polycystin”), TRPML (“Mucolipin”), 
and TRPA (“Ankyrin”). The TRPV subfamily (vanilloid receptors) comprises 
channels critically involved in nociception and thermo sensing. 
 
These receptors form a distinct subgroup of the transient receptor potential (TRP) 
family of ion channels. Members of the vanilloid receptor (TRPV) are activated by 
a diverse range of stimuli, including heat, protons, lipids, phorbols, phosphorylation, 
changes in extracellular osmolarity and/or pressure, and depletion of intracellular Ca
 
2+
 stores. However VR 1 remains the only only channel activated by vanilloids such 
as capsaicin. 
 
The TRPV 1 receptors have been found in the brain, spinal cord, and peripheral 
neurons, (Nakagawa H, 2006); eyes, (Leonelli M, 2011); smooth and cardiac 
muscles, vascular tissues, bronchial muscles, (Quest, J. A., 2004); GIT mucosa, 
(Barbara G, et al, 2003; and the urinary bladder, (Birder L. A., 2006).  
 
Most mechanistic studies of capsaicin-induced activation of nociceptive neurones 
have been made, by using cultured sensory neurons and isolated nerves in vitro 
(Cheng L, et al, 2009; Mogil and Basbaum, 2000; Wood, et al, 1989; Woolf, et al., 
1989). These studies show that capsaicin induces depolarization, during which there 
is an increase in the permeability to cations, particularly to calcium and sodium 
ions. Using specific antagonists such as capsazepine on capsaicin and its analogues, 
such as olvanil, nuvanil and resiniferatoxin; pharmacodynamic and pharmacokinetic 
studies on capsaicin were made possible. Dray (1992) has shown that the 
mechanisms by which, capsaicin produces desensitization, and inactivation of 
sensory neurons include receptor inactivation, block of voltage-activated calcium 
channels, intracellular accumulation of ions leading to osmotic changes, and 
activation of proteolytic enzyme processes. 
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In their study on sensory neuron-specific actions of capsaicin, Bevan and Szolcsanyl 
(1990) observed that capsaicin acts specifically on a subset of primary afferent 
sensory neurons to open cation-selective ion channels, probably by interacting 
directly with a membrane receptor-ion channel. The investigators indicated that 
other plant products and resiniferatoxin have structural similarities to capsaicin, and 
open the same channels. However, they found resiniferatoxin to be 1000 times more 
potent than capsaicin. In addition, they found that capsaicin-sensitive neurones are 
involved in nociception, responsible for the neurogenic component of inflammatory 
response, and may also have efferent actions on peripheral target tissues. In addition 
to its excitatory actions, they reiterated that capsaicin can have subsequent 
antinociceptive and anti-inflammatory effects. 
 
Besides TRPV1 receptors, RPM (Transient Receptor Potential Melastatin) had been 
implicated in Magnessium haemostasis in both the kidney and the intestine, 
Hoenderop J.G, et al, (2007); Schlingmann K.P. et al,, (2002); and Scmitz C., 
(2003). Mutations in TRPM6 have been found in inherited defects in Magnessium 
and Calcium uptake. 
 
The relationship between the TRPV and TRPM receptors is complex. Both 
receptors co-localises in the brain and tissues. Moreover, similar chemicals and 
drugs are able to stimulate both receptors in like manner. For example anadenamide 
and arvanil act on cannabinoids CB1 (as antiproliferative of breast cancer) via the 
TRPM receptor as well as antagonize the TRPV receptors Melck D et al, (1999). 
 
In their study on sensory neuron-specific actions of capsaicin, Bevan and Szolcsanyl 
(1990) observed that capsaicin acts specifically on a subset of primary afferent 
sensory neurons to open cation-selective ion channels, probably by interacting 
directly with a membrane receptor-ion channel. The investigators indicated that 
other plant products and resiniferatoxin have structural similarities to capsaicin, and 
open the same channels. However, they found resiniferatoxin to be 1000 times more 
potent than capsaicin. In addition, they found that capsaicin-sensitive neurones are 
involved in nociception, responsible for the neurogenic component of inflammatory 
response, and may also have efferent actions on peripheral target tissues. In addition 
 23  
to its excitatory actions, they reiterated that capsaicin could have subsequent 
antinociceptive and anti-inflammatory effects. 
 
 
2.5.2.      EFFECT OF pH CHANGES ON CAPSAICIN ACTIVITY 
 
In their study, Bevan and Winter (1995) found that at low pH, sensory neurones are 
stimulated, resulting in opening of ionic channels. Current evidence suggests that 
elevation of cations, including sodium and calcium ions, is activated through 
capsaicin channel itself (Peterson, et al., 1989). There is the thought that protons can 
be the endogenous activators of such channels (Sann et al., 1987). In ischaemic or 
inflamed tissues, pH can fall to such critical level, which, directly activate 
capsaicin-operated channels, and contribute to pain associated with pathological 
conditions (Bevan et al., 1992; Hegyi, et al., 2003). 
   
Capsaicin antagonists, such as capsazepine and ruthenium red, block some proton 
and capsaicin-evoked responses, e.g., smooth muscle contraction and CGRP release 
from smooth and skeletal muscles (Robertson et al, 1989; Bevan and Geppetti, 
1994). It is not conclusive if the protons open capsaicin-operated channels directly 
or indirectly through the release of another mediator. Moreover, Baumann et al., 
(1996) observed that both protons and capsaicin exert excitatory effects on human 
sensory neurons, and that by means of multiple membrane mechanisms, 
depolarization of cultured human dorsal root ganglon (hDRG) neurons occurs at low 
pH (Maggi et al.1988; Roza and Reeh, 2001; Olah, et al. 2001). The investigators 
also observed that inhibition of resting membrane conductances contributes to low  
pH in some human DRG neurons.  
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Figure 2.7. Some mechanisms of capsaicin action, Adapted from Wallace, M.S., 
(1997).   
 
2.5.3.     MODULATOR OF CAPSAICIN ACTIVITY 
Capsaicin sensitivity has been found to be dependent on the continued 
presence of nerve growth factor (NGF), whose concentration increases in inflamed 
tissues (Bevan and Winter, 1995). Antibodies that neutralize NGF completely 
inhibit the development or reverse, established hyperalgesia (both mechanical and 
thermal) following injection of complete Freund‟s adjuvant (CFA) into the rat paw 
(Lindsay and Harmar, 1989; Treede, et al., 1992; Woolf and Max, 2001). 
Furthermore, in vivo and in vitro studies have shown that NGF regulates several 
characteristics of nociceptive neurones, such as the content of neuropeptides, 
Substance P, and CRGP (Shir and Seltzer, 1990; Winter, et al., 1993).  The 
contribution of NGF-dependent up-regulation of capsaicin or proton sensitivity to 
inflammatory hypersensitivity is, however, not known.   
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2.5.4.    CAPSAICIN AND NEURAL DESENSITIZATION 
 
The role of capsaicin in desensitization of nociceptive neurones has been reviewed 
(Holzer, 1991). Two distinct modes of desensitization have been found. One of 
them is a classic pharmacological desensitization, where prolonged and repeated 
application of capsaicin leads to a progressive decline in the size of subsequent 
responses to capsaicin. The other is a functional desensitization, where a challenge 
with capsaicin leads to a reduction, or loss of responsiveness of, the neurone to 
other stimuli. Both modes occur together, but can be differentiated at low 
concentrations, at which end-point responsiveness to capsaicin is reduced or lost 
selectively, and responses to other stimuli are unchanged (Dray, 1992; Drummond, 
1998). Functional desensitization seen at higher concentrations of capsaicin is the 
basis for the analgesic and anti-inflammatory effects of capsaicin. 
 
The process of desensitization is calcium-dependent, as it does not take place when 
calcium is removed from the extracellular medium (Yeats, et al., 2003; Sann et al., 
1987; Cholwinski et al., 1993). The increase in intracellular calcium produced by 
capsaicin promotes desensitization by stimulating calcium- and calmodulin-
dependent cytosolic enzyme and protein phosphatase 2B (calcineurin). Calcineurin 
is inhibited by a complex of cyclosporin A, and its cytoplasmic binding protein, 
cyclophilin (Winter et al., 1995). Cyclosporin-cyclophilin complex abolishes 
capsaicin desensitization when introduced into the cytoplasm of rat sensory 
neurones. Increase in intracellular cyclic AMP increases capsaicin responses in 
sensory neurons (Yeats et al; 1992; Ritta and Dinh, 1993; Yoshimura et al., 2000). 
This observation suggests that sensitivity to capsaicin is regulated by 
phosphorylation of a key intracellular protein, which could be the receptor ion 
channel, or an associated protein (Lou et al., 1992; Mapp and Kidd, 1994). It was 
thus observed that capsaicin-induced functional desensitization requires the 
presence of extracellular calcium (Mapp and Kidd, 1994), which capsaicin 
antagonist, ruthenium red, blocks (Maggi et al., 1993; Attal, 2001).  
 
   Furthermore, it has been observed that capsaicin stimulates the release of excitatory 
amino acids (EAAs); such as glutamate and neuropeptides (CGRP, neurokinin A 
and Substance P), from both the peripheral and central terminals of sensory 
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neurones by two mechanisms (Gamse, 1982; Sann et al., 1987; Lynn et al., 1987; 
Kroll et al., 1990; Del Bianco et al., 1991; Lou et al., 1992; 1994; Woolf et al., 
1994). The influx of calcium through capsaicin-activated ion channels triggers 
release of EAAs independent of action potential generation and propagation. 
Depolarization evoked by the agonist effect of capsaicin is propagated to distant 
regions of the nerve to release glutamate and neuropeptides. Capsaicin has a longer-
term inhibitory effect, which is one likely mechanism for its analgesic and anti-
inflammatory actions (Woolf, 2000; Bleakman et al., 1990). Following capsaicin 
treatment, noxious stimuli no longer release glutamate and neuropeptides, despite 
the presence of near normal levels of neuropeptides in the nerves (Bevan and 
Geppetti, 1994). This inhibitory effect of capsaicin is due to a voltage-gated 
inhibition of calcium channels; thereby blocking the release of neurotransmitters 
from central and peripheral terminals (Rayner et al., 1989; Bleakman et al., 1990; 
Petersen and Rowbotham, 1999; Dinh et al., 2003). Thus inhibiting the transmission 
of noxious signals between nociceptive sensory neurone and spinal cord neurons; 
and reducing or eliminating neurogenic inflammation evoked by neuropeptide 
release from peripheral nerve terminals. Inhibition of voltage-activated calcium 
currents in rat DRG leads to analgesia and anti-inflammatory effects that are 
restricted to capsaicin-sensitive neurones occuring at low concentrations of 
agonism. There may be other unknown mechanisms of functional nerve block, such 
as depolarization block of action potentials, which may contribute to the cell- and 
agonism-specific effects of capsaicin. 
 
The effects of capsaicin on sensory neurones range from excitation to cell death. 
Many DRG neurones degenerate following neonatal capsaicin treatment. In vitro, 
the mechanisms of action of capsaicin-induced neurotoxicity was found to be 
osmotic, and partially through calcium entry, causing activation of calcium-sensitive 
proteases among other mechanisms (Chung et al., 1990). In vivo, the severity of 
these effects depends on factors such as age of animal at the time of treatment, route 
of administration, and the dose of capsaicin used. Systemic administration destroys 
many DRG neurones in neonatal rats (Jansco, 1992). Also in adult rats, many C-
fibre terminals degenerate (Chung et al., 1985; Chung et al., 1990) following large 
systemic doses, leaving many cell bodies to survive and regenerate (Lynn et. al., 
1987; Pini et al., 1990). Following perineural application of capsaicin, C fibres 
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degenerate distally with an extensive proximal axonal sprouting (Winter et al., 
1990; Winter et al., 1993; Jancso and Jancso-Gabor, 1977).  Although these 
damaged neurones in capsaicin-treated animals attempt to regenerate, they do not 
reinnervate, and the damage is essentially permanent. Following systemic capsaicin 
treatments, silver-staining method shows neurodegeneration in parts of the brain 
(Rayner et al., 1989). It was also observed that following systemic capsaicin 
treatments, there was depletion of neuropeptides, Substance P and CGRP, enzyme 
flouride-resistant acid phosphatase (FRAP) from DRG neurones, and appearance of 
vasoactive intestinal peptide (VIP), similar to the effects of surgical axotomy 
(Hayes et al., 1981; Jancso and Jancso-Gabor, 1997). 
  
 
2.5.5.    SUMMARY OF THE MECHANISMS OF THE ACTION OF                 
CAPSAICIN 
 
 In summary, the mechanism of action of capsaicin is based on neuronal 
desensitization to noxious stimuli. Desensitization is a capsaicin-induced loss of 
responsiveness to further capsaicin treatment. It is reversible. Desensitization is 
calcium dependent, and probably involves activation of a phosphatase, which 
inactivates capsaicin channel. 
 
Functional desensitization is a loss of sensitivity to a range of noxious stimuli, and 
underlies the analgesic effects of capsaicin. Functional desensitization is reversible, 
and may also depend on calcium-dependent dephosphorylation of other intracellular 
proteins, such as enzymes or ion channels. 
 
Neurotoxicity is induced by high doses of capsaicin. Axonal and terminal 
degeneration and impaired nociception appear to be irreversible. Both osmotic lysis 
and action of calcium-dependent proteases may be responsible for capsaicin-
induced neurotoxicity (Winter et al., 1995; Cervero, et al. 1983; Nolano, et al., 
1999; Phylis, 1986). 
 
In acute pain, studies in animals have shown that systemic capsaicin relieves pain in 
increasing doses from 0.5 mg/kg to 10 mg/kg, but nerve degeneration was noted in 
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doses of 50 mg/kg and greater. The relief was for mechano-thermal pain (Hayes et 
al., 1981; Nagy and Van der Kooy, 1983; Jansco, 1992; Epstein and Marcoe, 1994).  
In human studies, it requires days to weeks before beneficial effects of capsaicin can 
be seen (Carpenter and Lynn, 1981; Colpaert et al., 1983; Davis et al., 2000).  
 
With an increase in the levels of Substance P in inflammatory and neurogenic joint 
diseases (arthritis), topical or intra-articular injections of capsaicin have shown 
significant improvements, as well as reductions in level of inflammatory mediators 
(Colpaert et al., 1983; Levin et al., 1984; Marshall et al., 1990; Davis and Perkins, 
1994; Davis et al., 2000). In the same vein, Perkins and Campbell (1992) used 6 
mg/kg of intra-articular capsaicin to reverse mechanical hyperalgesia for several 
hours (Campbell et al., 1993). 
 
In rheumatoid arthritis, the effect of capsaicin is mixed. Whereas Deal et al. (1991) 
showed significant reduction in the level of pain intensity in 31 patients with 
rheumatoid arthritis of the knee following treatment with zostrix (as 0,025%) for 4 
weeks, McCarthy and McCarty (1992) did not observe any improvement in 7 
patients with rheumatoid hands, using 0.75% capsaicin. However, Weisman et al. 
(1994) reported that application of capsaicin (0.75%) for 6 weeks produced a 
reduction in inflammatory mediators, including Substance P, in the synovial fluid of 
patients with rheumatoid arthritis. In osteoarthritis, there is evidence to show 
increase in the level of Substance P in patients (Menkes et al. 1993; McCarty et al. 
1994). Randomized, controlled trials have also shown significant improvement in 
pain relief following treatment with capsaicin cream (Deal et al., 1991; Knight and 
Hayashi, 1994; Mapp and Kidd, 1994; McCleskey and Gold, 1996). 
 
With neuropathic pain in mind, animal studies using intrathecal as well as 
subcutaneous or topical capsaicin have produced significant improvements in the 
relief of hyperalgesia and pain (Attal, 2001; Berring et al., 1990; Kim et al., 1992; 
Meller et al., 1992; Sinoff and Hart, 1993; Winter et al., 1995). These studies show 
that capsaicin-sensitive nerves have a role in thermal hyperalgesia in the animals 
under study (Winter et al., 1995; Witting, et al., 2000). 
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Studies in humans with neuropathic pain include patients with post-herpetic 
neuralgia (Berring et al., 1990; Peikert et al., 1991; Simone and Ochoa, 1991; 
Santicioli et al., 1987; Lee and Gauci, 1994), diabetic neuropathy (Santicioli et al., 
1992; Capsaicin Study Group, 1999), and post-mastectomy pain (Dini et al., 1993; 
Watson et al., 1989; Watson and Evans, 1992; Watson et al., 1993). Others include 
the use of capsaicin in stump or phantom pain (Rayner, et al., 1989; Winter et al., 
1995; Baron, 1998); Complex Regional Pain Syndrome Type I (Siertsema et al., 
1988); Trigeminal Neuralgia (Fusco et al., 1991); and oral neuropathic pain (Epstein 
and Marcoe, 1994). Capsaicin was also studied in cluster headache (Santiciolli et 
al., 1987, Fusco et al., 1991; Epstein and Marcoe, 1994; Marks et. al., 1993), 
fibromyalgia (McCarty et al., 1994), as well as in acute or chronic conditions, such 
as osteoarthritis (Deal et al., 1991; McCleskey and Gold, 1996); and rheumatoid 
arthritis (Deal et al., 1991), respectively. 
 
Notable among these studies are those by the Capsaicin Study Group (1999) with a 
total of 277 patients (138 capsaicin 0.075%, 139 placebo) having diabetic 
neuropathy. The Group reported significant improvements in all measures (pain, 
walking, working, and sleeping) after administering capsaicin four times daily for 
up to eight weeks. In their study, Jensen and Larson (2001) found that capsaicin 
cream provides an alternative treatment option with a favourable outcome in painful 
diabetic neuropathy. Most of these studies were performed over similar periods of 
time, except the study by Watson et al. (1993), which followed up 83 patients with 
post-herpetic neuralgia for two years. The investigators found that in 86% of their 
patients, improvements in the pain scores were either maintained or further 
enhanced with no serious side effects. Furthermore, the efficacy of nasal application 
of capsaicin in the treatment of cluster headache had been confirmed following 
seven days application of capsaicin with significant improvement when compared 
with placebo. The relief might have been produced through the effects of capsaicin 
on Substance P-containing trigeminal nerve (Marks, 1993; Kowalsaki, 1999). 
 
Capsaicin has also been shown to relief pruritus in patients with psoriasis 
(Kurkccuoglu and Alaybeyi, 1990; Ellis et al., 1993); brachioradial pruritus 
(Goodless and Eaglstein, 1993); aquagenic pruritus (Lotti et al., 1994); notalgia 
parasthetica (Leibosohn, 1992); nodular prurigo (Goodless and Eaglstein, 1993); 
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and pruritus produced in patients on haemodialysis (Brand et al., 1987). In human 
volunteers, capsaicin treatment was found to have inhibited itch after histamine and 
allergen challenge. Itch is mediated by a subset of capsaicin-sensitive nociceptive 
neurones through the inhibition of C fibre conduction (Lynn et al., 1987; McMahon 
and Kotzenbeerg, 1992). 
 
The wide systemic side effects have made topical capsaicin to be more acceptable in 
clinical state. The main side effects are neuronal, cardiovascular, muco-cutaneous 
tissue, or open wounds. Electron microscopic observations have revealed 
degeneration and glial engulfment of buttons and unmyelinated axons in the dorsal 
horn, 2-6 hours after neonatal subcutaneous capsaicin injections in rats. There is 
increased latency of the nerves; convulsion and even death may follow very high 
doses of capsaicin (Lee et al., 1991; Simone, et al., 1989). Cannabinoids have been 
used to attenuate capsaicin-evoked hyperalgesia (Johanek, et al., 2001), and low 
dose lidocaine was found to reduce capsaicin-evoked secondary hyperalgesia by a 
central mechanism (Koppert, et al., 2000). 
 
When capsaicin is in contact with muco-cutaneous tissues, such as the conjunctiva, 
it produces intense inflammatory reaction (Surh and Lee, 1995). This is consequent 
upon the initial release of Substance P. Cardiovascular studies on blood vessels have 
shown that both capsaicinoids and capsaicin could inhibit vasoconstriction induced 
by norepinephrine (Kinnmann, et al. 1997), and the vasodilatation effect of 
capsaicinoids might be due to the action of capsaicin.  The compounds also cause 
significant decreases in platelet aggregation induced by ADP and collagen; and 
increase blood flow in volunteers. During their study in Thailand, Jaiarj et al. (1998) 
first noticed that people who consume large amounts of red chilli peppers 
experienced a lower incidence of thrombo-embolism, or potentially dangerous 
blood clots. 
 
The alternative to the mixed actions of capsaicin is being looked into through the 
development of purer and more potent capsaicin analogues (Szallasi and Blumberg, 
1990). Brand et al. (1990) and Breneman et al. (1992) reported significant thermal 
and mechanical analgesia and anti-inflammatory activity following administration 
of olvanil oleamide, an analogue, which lacked the acute toxicity of capsaicin. 
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Nuvanil was found to be more soluble, thus allowing for oral administration, and 
also showed improved oral activity and significant analgesia (Yang, et al., 1992; 
Yakish, 1999). The compounds were also found to show less pungency and reduced 
vagally mediated blood pressure reflexes (Brand et al. 1990; Breneman et al. 1992; 
Walpole et al. 1993; Hua et al. 1997; Jaiarj et al. 1998). In this regard, Lee et al. 
(1991) and Lee and Gauci, (1994) discussed how acute toxicity of capsaicin can be 
prevented through structural modification. Moreover, Chen et al. (1992) and Hua et 
al. (1997) also reported that orally active capsaicin analogue, civamide, showed a 
significant increase in response latency on the thermal withdrawal test that persisted 
for three days in adult rats.  
 
In their three studies, Walpole et al. (1993) reported a series of structure-activity 
relationships based on different parts of capsaicin molecule, and described a rational 
basis for the design of compounds with increased potency. The investigators 
concluded that capsaicin antagonists, such as capsazepine and ruthenium red, inhibit 
capsaicin-induced analgesia and anti-inflammatory actions. 
 
From the synopsis above, it is obvious that capsaicin is a cell-specific peripheral 
analgesic. Agonism, that is, the ability to open capsaicin-operated channels, is 
required for efficacy. There is a growing body of evidence for the efficacy of 
capsaicin in a number of painful conditions. A better window between analgesic 
doses and doses that produce side-effects is required for an orally-active therapeutic 
drug. However, topical applications of capsaicin are effective and without side-
effects (Winter et al., 1995; Bernstein, 1998). There is also a growing body of 
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CHAPTER 3 
MATERIALS AND METHODS 
 
 
3.1.      RESEARCH METHODOLOGY 
 
Experimental procedures and protocols used in this study were approved by the 
Animal Ethics Committee of the University of Durban-Westville, Durban 4000, 
South Africa (now University of KwaZulu- Natal; Westville Campus), and conform 
to the “Guide to the care and use of animals in research and teaching” (published 
by the University of Durban-Westville, Durban 4000, South Africa).  
       
3.2.1.   EXPERIMENTAL PROTOCOLS 
 
Experimental protocols were written so as to lay down the organisation of the study. 
The sequence of this study follows the following structure: 
 
      1. Purchase of Capsicum frutescens from a local market in Durban. 
2. Identification of Capsicum frutescens by a Botanist (Prof. Himansu Baijnath). 
3. Extraction and purification of Capsicum frutescens fruit. 
4. Identification of capsaicin from Capsicum frutescens fruit extract by Nuclear 
Magnetic Resonance (NMR). 









 55  
3.2.2.   PLANT MATERIAL AND PREPARATION OF  
                    EXTRACT 
 
Capsicum frutescens Linn. (family:Solanaceae) fruits were purchased from 
Warwick market in Durban, South Africa. The fruits were identified and 
authenticated by a botanist, Professor Himansu Baijnath. A voucher specimen of the 
plant (with its ripe fruits) has been deposited in the University‟s Herbarium 
(JAT/01). The total weight of the dried red chilli pepper fruits purchased from the 
local market was 3 kg. Dry ripe fruits of the Capsicum frutescens were separated 
from the stalk, cleaned and pulverized, using a mechanical grinder. Two-and-a half- 
kilogram of the powder was put in a big conical flask and exhaustively extracted 
sequentially in hexane, dichloromethane and ethylacetate. Preliminary pilot 
experiments show that the ethyl acetate extract contains active compounds 
(capsaicinoids). The ethyl acetate extract was concentrated in a rotary evaporator 
under reduced pressure to yield 298 gm (10% yields) of the crude extract.  The ethyl 
acetate extract was further purified. NMR analysis of the yield shows 98% 
capsaicin. Throughout this study, the 98% capsaicin aqueous extract of Capsicum 
frutescens was used. 
 
3.2.3.        CHROMATOGRAPHIC FRACTIONATION 
 
A portion of the crude ethyl acetate extract was subjected to column 
chromatography over silica gel with gradient elution using 10% ethyl acetate in 
hexane to 40% ethyl acetate. A total of 51 eluates (25 ml each) were collected and 
combined into 15 fractions on the basis of their TLC similarities. The non-polar 
fractions (1-3) were chlorophyls, etc; and were discarded. The semi-polar/polar 
fractions (4-15) were subjected to further column chromatography over silica gel 
with gradient elution (30% ethyl acetate in hexane to 50% ethyl acetate). TLC was 
carried out on pre-coated aluminium plates using Merck Si gel F254. The developed 
TLC plates were visualised under UV light (254 and 366 nm), and by spraying with 
anisaldehyde/sulphuric acid/alcohol solution, and heated at 110
0
C for 5 min. 
Appearance of blue to violet-blue colouration indicated the presence of 
triterpenoids, as previously reported (Hostettmann and Marston, 1995 cited by 
Wilson and Walker, 1999). NMR spectra (1D and 2D) were obtained on a Varian 
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300 (300 MHz) spectrometer, using the residual solvent peaks as internal standards 




FLOW CHART FOR THE EXTRACTION OF CAPSICINOIDS FROM 
CAPSICUM   Spp 
  
 
Figure 3.1.  Flow chart: Extraction of capsaicinoids from Capsicum and 




















 pressure)  
1. Wash (50g) with 
aqueous acetate. 
2. Extract aq. acetone 
layer with DCM 
3. Dry organic layer 
filter and concentrate. 
4. CC treatment 
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DATE                         24/06/03 
CODE NO                  DP /14 
QUANTITY OF EXTRACT: 5.042 G 
 





Wt (g) GENERAL 
REMARKS 
E 3 DP 14/k1 0.351 A mixture of 2 
compounds 




DP 14/K3 0.147 A mixture of 2 
compounds 
E18 DP 14/K4 0.108 A mixture of 2 
compounds 
E24 DP 14/K5 0.084 A pure sample 
E 30 DP 14/K6 0.103 A mixture of 2 
compounds 
E 36 DP 14/K7 0.037 A pure sample 
E39 DP 14/K8 0.055 A pure sample 
E 42 DP 14/K9 0.211 A mixture of 2 
compounds 
E 45 DP 14/K10 0.011 A mixture of 4 
compounds 
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Chromatography of crude extracts of Capsicum frutescens. 
 
 DATE                         25/06/03 
 
CODE NO                  DP /15 
 
QUANTITY OF EXTRACT: ~ 2g 





Wt (g) GENERAL 
REMARKS 
E1- E4 DP 15/L1 0.142 A mixture of 2 
compounds 
E2-E17 DP 15/L2 0.218 A mixture of 4 
compounds 
13-E18 DP 15/L3 0.168 Pure sample 
E14-E36 DP 15/L4 0.173 Pure sample 
E32-E48 DP 15/L5 0.101 Pure sample 
E49-E51 DP 15/L6 0.005 A mixture of 2 
compounds 
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Chromatography of crude extracts of Capsicum frutescens. 
 
DATE                         27/06/03 
 
CODE NO                  DP /16 
 
QUANTITY OF EXTRACT: Unknown weight 
 





Wt (g) GENERAL 
REMARKS 
E1-E3 DP 16/M1 0.305 A compound of  3 
mixtures 
E4-E6 DP 16/M2 0.452 A compound of 4 
mixtures 
E8-E12 DP 16/M3 0.821 A compound of  3 
mixtures 
E13-E18 DP 16/M4 0.328 A compound of 4 
mixtures 
E14-E21 DP 16/M5 0.153 A compound of  2 
mixtures 
E21-E22 DP 16/M6 0.208 A compound of  3 
mixtures 
E28-E42 DP 16/M7 0.053 A compound of  3 
mixtures 
E29-E43 DP 16/M8 0.523 A compound of  2 
mixtures 
E48-E54 DP 16/M9 0.088 A compound of  3 
mixtures 
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Chromatography of crude extracts of Capsicum frutescens. 
   
 
DATE                        12/08/03 
CODE NO                  DP /27 
 
QUANTITY OF EXTRACT: Unknown weight. 





Wt (g) GENERAL 
REMARKS 
E1-E6 DP 27/R1 0.002 Pure Sample 
E7-E15 DP 27/R2 0.003 A mixture of 2 
compounds 
E6-E18 DP 27/R3 0.004 A mixture of 2 
compounds 
E19-E24 DP 27/R4 0.051 A mixture of 2 
compounds 
E25-E36 DP 27/R5 0.084 Pure sample 
E31-E42 DP 27/R6 0.029 Pure sample 
E43-E44 DP 27/R7 0.047 A mixture of 2 
compounds 
E40-E46 DP 27/R8 0.281 Pure sample 
E52-E48 DP 27/R9 0.024 A mixture of 2 
compounds 
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        Figure 3.3.   Filtration to remove extract of Capsicum frutescens fruit. 
  
Figure 3.4.  Gentle heating of powdered Capsicum frutescens fruit in the solvent 
(methanol or ethyl acetate). 
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Figure 3.5. Column chromatography and separation of capsaicinoids.” 3-4 
different substances can be identified according to colour.  
 
 
3.3.      CHROMATOGRAPHY 
Chromatograph is one of the various techniques used for the separation of complex 
mixtures that rely on differential affinities of substances for a gas or liquid mobile 
medium, and for a stationary adsorbing medium through which they pass (such as 
paper, gelatin, or magnesia), [American Heritage Dic. of the English Language, 4th 
ed.]. 
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3.3.1.       BASIC   PRINCIPLES 
The basis for all forms of chromatography is the partition or distribution coefficient 
(kd), which describes, the way a substance is distributed between two immiscible 
phases (Wilson and Walker, 1999). Any chromatography consists of a stationary 
and a mobile phase. The stationary phase may be solid, gel, or a solid/liquid 
mixture. In this study, the stationary surface is solid-silica.  The mobile phase is 
usually gaseous or liquid, which flows over or through the stationary phase.  In this 
study, the mobile medium was hexane, methanol, dichloromethane (DCM), or ethyl 
acetate.   
The choice of stationary and mobile phases is such that the compounds to be 
separated have different distribution coefficients.  There are various methods that 
can be used to achieve this, which includes the setting up of:  
(i) an adsorption equilibrium between the solid and liquid phases. Examples 
are adsorption and hydrophobic interaction chromatography, 
respectively.  
(ii) Partition equilibrium may be set-up between a stationary liquid phase 
and a mobile liquid phase, such as in partition chromatography; 
reversed-phase chromatography; ion-pair chromatography; chiral 
chromatography; gas chromatography and countercurrent 
chromatography. 
In ion-exchange chromatography and chromatofocusing, ion-exchange equilibrium 
between a stationary ion exchanger and mobile electrolyte phase is set-up. In 
exclusion or gel chromatography; equilibrium is set-up between a liquid phase 
trapped inside the pores of a stationary porous structure, and a mobile liquid phase. 
However, in affinity and immuno-affinity chromatography, equilibrium is set-up 
between a stationary immobilized ligand and a mobile phase. Other examples of this 
form of set-up are lectin affinity, metal-chelate; dye-ligand and covalent 
chromatography. 
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In practice, two or more of these equilibra may be involved simultaneously in a 
particular chromatographic separation. In the present study, both adsorption and 
partition equilibra were set-up between the mobile and stationary phases.  
Movement of individual species from the mobile phase through the solid phase is 
affected by such retarding factors as the relative solubility, surface adsorption and 
the charge of the particles.  
The two theories governing chromatographic processes are the „rate‟ and „plate‟ 
theories. In the plate theory, chromatographic column is treated as though it was a 
static system in equilibrium. Each system exhibits equilibrium between the mobile 
and stationary phase. 
A mobile phase ↔ A stationary phase 
The plate theory assumes that the chromatographic column is mathematically 
equivalent to a plate column. Equilibrium is established for the solute between the 
mobile and the stationary phase. It is a useful theory and can predict many aspects 
of chromatographic performance. From the foregoing, it will be seen that 
chromatography is useful for both quantitative and qualitative analysis.  
Quantitatively, chromatography depicts that there is a presence of a substance in the 
column; but it does not state the quantity of the substance. Qualitative analysis then 
shows what the quality of the substance is through electron capture or ion detector 
(Parbrook et al., 1989; Sykes, et al., 1999).  In this study, Nuclear Magnetic 
Resonance (NMR) was used (in collaboration with the Chemistry Department of the 
University of KwaZulu-Natal) to identify the final extract, i.e. capsaicin. 
Chromatographic separation can be achieved using three contrasting modes. They 
are column chromatography, thin layer chromatography and paper chromatography. 
In column chromatography, the stationary phase is attached to a suitable matrix (an 
inert, insoluble support) packed into a glass or metal column.  The mobile phase is 
passed through the column either by gravity feed (as in this study) or by the use of a 
pumping system, or applied gas pressure. This is the most common form of 
chromatographic modes. In thin layer chromatography, the stationary matrix is 
coated thinly on to a glass, plastic or metal foil plate. The mobile liquid phase across 
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the thin-layer plate held either horizontally or vertically, is by capillary action.  Its 
advantage is that a large number of samples can be studied simultaneously. In paper 
chromatography, the stationary liquid phase is supported by cellulose fibres of a 
paper sheet. Thin layer and paper chromatography have several similarities. In both 
modes, the mobile phase passes along the paper sheet either by gravity feed, or by 
capillary action. It is one of the older forms of chromatography, with few current 
serious biochemical applications.   
The flow rate is determined by the physical dimensions of the column, (internal 
diameter, length), particle size, shape and porosity, and the viscosity of the mobile 
phase.  In a liquid partition chromatographic column, the elution volume is related 
to the volume of the stationary phase, Vs, the distribution coefficient, kd, of the 
analyte between the stationary and mobile phases, and to the void volume or dead 
space, VM, of the mobile phase around, and within the packed stationary phase 
particles, by the equation: 
                                      VR= VM+ KdVs 
The surface area of the adsorbent, As, replaces Vs in adsorption column 
chromatography. VR is the retention volume. 
The most important parameters in column chromatography is the unitless capacity 
ratio. This is a measure of the time spent by the analyte in the stationary phase 
relative to the time spent in the mobile phase. It reflects column performance. 
The success of a particular chromatographic system is determined by its ability to 
achieve good resolution which, is determined by the selectivity, efficiency and the 
capacity of the system. The „selectivity‟ is a measure of the inherent ability of the 
system to discriminate between structurally related compounds.  The „efficiency‟ is 
a measure of the diffusion effects that occur in the column to cause peak broadening 
and overlap. The „capacity‟ is a measure of the amount of material that can be 
resolved without causing peaks to overlap, irrespective of such action as gradient 
elution and temperature programming. 
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The stationary phase is packed according to standard procedure with matrices 
attached in a range of sizes and shapes. A 100-200 mesh is most common for 
routine use, or 200-400 mesh used for higher resolution work.  Poor column packing 
gives rise to uneven flow (channeling) and reduced resolution. 
In order to ensure that the chromatographic systems were up to standard, phase A of 
this study was conducted in the Chemistry Department under the supervision of a 
Professor of Analytical Chemistry (Prof. Francis O Shode).                     
3.4.         OTHER TYPES OF CHROMATOGRAPHY 
3.4.1.           PAPER CHROMATOGRAPHY 
 
In paper Chromatography, a high-quality filter paper is impregnated with a very 
sensitive indicator. Using capillary action, the solute dissolved in a solvent in which 
the paper is dipped, travels at different rates across the filter paper. The paper is 
fixed and dried in a fume chamber. 
  




        Figure 3.7. Fume chimneys for spraying and flushing. 
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For example, in Congo red paper, paper is impregnated with Congo red; used as a 
pH indicator, changing from blue-violet at 3.0 to red at 5.0.  
 
  
Figure 3.8.  Paper chromatograph following spotting, spraying and drying in an oven. 
  
 Figure 3.9. Two or three main substances evolve following oven treatment. 
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       Figure 3.10. Chromatograph papers at the end of each oven drying. 
  
        Figure 3.11. Chromatography of pure capsaicin in action. 
 
  
        Figure 3.12.  Thin layer paper chromatography. Different rate of diffusion was     
       facilitated by capillary action which helps to separate the 3-4 capsaicinoids. 
3.4.      GAS CHROMATOGRAPHY 
In gas chromatography, the substance to be separated into its components is diffused 
along with a carrier gas through a liquid or solid adsorbent for differential 
adsorption, [American Heritage Dic. of the English Language, 4
th
 ed.]. 
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Figure 3.13. NMR profile of capsaicin-courtesy of Prof Shode, Department of 
Organic Chemistry UKZN/2005 
 
3.5.1.   ANALGESIC/NEUROPHARMACOLOGICAL STUDIES 
 
Experiments were performed on male mice (20-30 g body weight). The mice were 
maintained under conventional laboratory conditions of 12-h light/12-h dark regime, 
temperature and humidity. The animals were fed with standard diet pellet (Epol-
4700, Epol, South Africa) and drinking tap water ad libitum. They were kept in the 
Biomedical Resource Centre, University of KwaZulu- Natal, Durban, South Africa 
and treated according to best practice in animal experimentation (Jasper and Nelkin, 
1992; Midgeley, 1983; Tannenbaum, 1995; Baird and Rosenbaum, 1991). The „hot 
plate‟ and „acetic acid‟ analgesic tests methods were used for central and peripheral 
nervous system investigations on pain mechanisms, using the mean reaction time 
and inhibition of writhings, respectively. 
 
3.5.2.       ANTI-INFLAMMATORY STUDIES 
 
Healthy, albino rats (250-300 g) of both sexes were used. They were obtained from 
the Biomedical Resource Unit of the University of KwaZulu-Natal, and were 
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divided into six groups of 10 rats per group. The animals were kept and maintained 
under standard laboratory conditions of temperature, humidity, and light. The 
animals were fed with standard diet pellet (Epol-4700, Epol, South Africa) and 
drinking tap water ad libitum (Baler, 1983; Brink, 2006; Cohen, 1986; Frey, 1987). 
The circumferences of both hind paws of the rats were measured. They were either 
pretreated with capsaicin or normal saline. Fresh egg albumin was then injected into 
the rats‟ right subplantar hind paws as a phlogistic agent. After 30 mins, the 
circumferences of the right hind paws of the rats were measured at 30 min, 1, 2, 4, 
12 hours respectively. Comparative analysis between the control and treated groups 
were made, respectively.   
 
 
 3.5.3.       EXTRAVASCULAR SMOOTH MUSCLE STUDIES 
Healthy, young adult, white albino rabbits of both sexes weighing 1.5–3.0 kg; male 
and female Dunkin-Hartley guinea pigs weighing 300–450 g; young chicks (aged 
between 3 and 10 days after hatching), were used. The animals were kept and 
maintained under standard laboratory conditions of light, temperature, and humidity 
(Dennis, 1997; Feinberg, 1980; Fox, 1986). The animals were fed with standard diet 
pellet and drinking tap water ad libitum. The effects of Capsicum-derved capsaicin 
on chick isolated parasympathetically-innevated oesophagus, rabbit duodenum, and 
guinea-pig ileum were investigated in Ugo Basile organ-baths containing Krebs 
phusiological solution maintained at 35
0
 C, respectively. In all cases, concentration-
response curves to standard agonists were investigated in the absence and in the 
presence of capsaicin (CPE), or standard antagonists. 
 
 
3.5.4.       HAEMATOLOGICAL TEST 
 
A pilot study consisting of 12 Witstar rats (250-300 g) treated orally with 50 mg/kg 
of Capsicum frutescens fruit extract was carried out. Tissue morphology was 
examined grossly from the oesophagus to the intra-abdominal organs. 
 
In the definitive study, Witstar rats weighing 250–300 g were divided into two 
groups (A and B) of „control‟ and „treated‟ rats, respectively. All the animals were 
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fed with standard diet pellet (Epol-4700, Epol, South Africa) and drinking tap water 
ad libitum, unless otherwise indicated (Goodwin, 1992; Goodwin and Morrison, 
1993; Hume, 1968). Group A consisted of 12 untreated animals as control, while 
group B consisted of 3 treatment groups of 12 animals per group and were treated 
with capsaicin extract (2.5, 5.0, or 10.0 mg/kg i.p.), respectively. Following 
treatment, 1.5-2 ml blood was collected by cardiac puncture following deep 
halothane-anaesthesia. The blood specimens were analysed for platelets, as well as 
the Internationalised Normalised Ratio (INR) of prothrombin. In a parallel study, 3 
groups of 12 Witstar rats and 3 groups of 12 rabbits per group were treated with 8 
mg/kg of capsaicin extract daily for 2 weeks. Two millilitres of blood was collected 
from each animal by intracardiac puncture following deep halothane anaesthesia in 
the rats, and anaket/midazolam anaesthesia in the rabbits. The specimens were 
analysed for urea and creatinine.  
 
3.6.           CARDIOVASCULAR STUDIES 
 
Six rats‟ hearts were prepared in a 50-ml Laggendorf's Apparatus for each escalated 
dose of capsaicin, including 0.05, 0.1, 0.2, 0.4, 0.6, 0.8 and 1.0 µg/ml of capsaicin, 
respectively. The end points measured were changes in the heart rate, coronary 
perfusion pressure, left ventricular pressures and the left ventricular contractions 
(dp/dt), using a constantly perfused rat heart in Laggendorf's preparation.  
 
In some preparations, following capsaicin treatments, the hearts were exposed to 30 
min ischaemia followed by 60 min reperfusion. The hearts were then treated with 
1% triphenyltetrazolium chloride (TTC), an agent that stains cardiac tissues, and 
allows them to retain their architecture. Histopathological slides of the hearts were 
prepared and examined for evidence of ischaemia and/or infarction. The results 
were compared with the controls. 
 
3.7.    DATA ANALYSIS  
 
Experimental data obtained were pooled and presented as means (+SEM). Data 
from „control‟ rats were used as baseline values. The mean reaction times to the 
pain stimulus or the writhings were recorded and subsequently analysed using a 2-
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way ANOVA. Wilcoxon and Kruskal-Wallis tests were used to assess any 
differences. Student‟s t-test was used to test for the difference between the means 
when two groups were analysed. Where the groups are more than two, ANOVA was 
used to test for differences between the groups.  
 Statistical significance was by using a double tailed CI of 95%, and a P value of 
less than 0.05 (Moore and McCabe, 1993). Pearson correlation coefficient was used 
to assess the activity of Capsicum frutescens-derived capsaicin extract, compared to 
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CHAPTER 4 
 
Analgesic/Neuropharmacological Effect of capsaicin 
 
Analgesic effects of Capsicum frutescens Linn. [Solanaceae] fruit 
aqueous extract in mice  
 
SUMMARY: The analgesic property of Capsicum frutescens LINN. 
SOLANACEAE] extract-CFE (98% Capsaicin by NMR) of South African origin in 
mice (20-30 g), using „hot plate‟ and „acetic acid‟ methods was investigated. In the 
hot plate test, twelve mice in each of 5 groups were administered intraperitoneal 
(i.p.) CFE or synthetic capsaicin (Fluka Biotechnika-CF) at 0.5-8 mg/kg and at 
hourly intervals; at 40 C, the mean reaction time (MRT) was estimated. In the 
„acetic acid‟ test method, CFE or CF was administered i.p. at various doses (0.5- 8 
mg/Kg) at hourly intervals following single treatment using 0.2 mls of 3 % v/v 
acetic acid-induced writhing responses, or non treated (n=12). Separate groups of 
rats (n=12) were pre-treated with 100-mg/kg diclofenac (DIC) or morphine (MPN) 
10 mg/kg i.p. to evaluate the peripheral analgesic effects and central analgesia, 
respectively. Data obtained were pooled and analysed by the student‟s T-test. The 
„hot plate‟ and „acetic acid‟ test methods showed significant (p<0.0001) 
prolongation of the MRT and inhibition of writhing responses, respectively, 
compared to the control. Similar results with a Pearson correlation of 0.999 were 
obtained in the CF subgroups.This study shows that capsaicin has superior central 
analgesia compared to equipotency doses of MPN or DIC and comparable 
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4.1.        INTRODUCTION 
 
Chronic pain is a major health hazard resulting in debilitation, sickness role, and 
adverse drug reactions, including death (Jolayemi, 2002). Pain management is 
multidisciplinary, with current trend emphasising complimentary health methods 
(Wallace, 1997;).  This multi-specialty approach is unaffordable for patients in 
developing countries (due to poor socio-economic conditions), resulting in poor 
compliance, self-medication and high complication rate, or death. A review of the 
evolution of analgesics shows that they are derived primarily from basic foods, 
natruceaticals, and other edible or chewable substances, and later from conventional 
medications. For example, poppy leaf and cannabinoid tea, or chewing of opioids or 
addictive substances; have been known to certain ethnic groups, for centuries. It is, 
therefore, important to use these natural interventions in a more scientific and 
beneficial way to improve compliance and health; and reduce the unwanted side-
effects of conventional analgesics. The development of inhibitors of Substance P of 
plant origin (reviewed by Bevan et al., 1995) provides an opportunity in the 
treatment of intractable pain.  
 
Capsicum species occur worldwide, and has been used for more than 9000 years by 
the Chinese, Indians, and Africans for medicinal and non-medicinal purposes (Watt, 
1962). One of the main objectives of this study was to determine if Capsicum 
frutescens fruit extract of South African origin, has similar efficacy on peripheral 
and central components of pain as described for Capsicum spp (Linn) [Solanaceae] 
in other parts of the world, such as India, Mexico, Thailand and South America 
(Jaiarj  et al., 1998).  
 
Studies described in the literature suggest that capsaicin could modulate analgesia 
(Bevan, 1990; Winter, 1997). Capsaicin extracted from Capsicum spp act at the 
vanilloid receptors to inhibit Substance P, and has proved very useful in intractable 
pain of diabetic neuropathy, as well as herpetic and trigeminal neuralgia (Davis, 
2000). Most of these studies have shown the analgesic effect of capsaicin in spinal 
mechanism. The questions that remain unanswered include elucidation of central 
and peripheral analgesic mechanisms of capsaicin. The protection of pre-treated rats 
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from thermal pain in the „hot plate‟ test method as described by (Ojewole, 2002) 
and the percentage inhibition of writhings in the pre-treated rats using the „acetic 
acid‟ test method were used in this study. 
  
 
4.2.           ANIMALS 
 
Experiments were performed on mice (20-30 g body weight) of both sexes. The 
mice were maintained under standard laboratory conditions of light, temperature 
and relative humidity. The animals were fed with standard diet pellet (Epol-diet 
4700, Epol, South Africa) and drinking tap water ad libitum. They were kept and 
maintained in Biomedical Resource Unit, University of KwaZulu-Natal, Durban 
4000, South Africa.  
 
4.3.1    DRUGS 
 
Investigative drugs included capsaicin (Fluka-Biotechnika), Capsicum frutescens-
derived extract, and positive controls (morphine) and diclofenac. 
 
4.3.2. ASSESSMENT OF ANALGESIC EFFECTS OF 
CAPSAICIN USING THE ‘HOT PLATE’ TEST METHOD  
 
The „hot-plate‟ (thermal) test method employed in this study was modified from 
those described in detail earlier by Eddy and Leimback, (1953) cited by Ojewole, 
(2006); Lanhers et al., (1992); and Williamson et al., (1996) cited by Ojewole, 
(2006). Mice weighing 20–30 g were divided into two groups (A and B) of control 
and treated animals. Group A had three subgroups of 12 mice each. The first 
subgroup consisted of untreated mice, the mice in second and third subgroups were 
treated with morphine (MPN, 10 mg/kg i.p.) and diclofenac, (DIC 100 mg/kg i.p.), 
respectively. Group B consisted of 2 main subgroups treated with Capsicum fruit 
aqueous extract (CFE) and CPF as the reference drug. Each subgroup was 
subdivided into 5 subunits based on the dose regimen of 0.5-8 mg/kg i.p. The 
animals had similar demographics in terms of sex, age and weight. All the animals 
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were fed with standard diet pellet and drinking tap water ad libitum. A 600-ml glass 
beaker was placed on a „Heidolph MR 2002‟ hot-plate (with adjustable 
temperature). The temperature of the hot-plate was then regulated to 40  1
o
C. Each 
mouse was placed in the glass beaker (on the hot-plate) in order to obtain the 
animal‟s response to electrical heat-induced nociceptive pain (licking of the 
forepaws and eventually jumping out of the glass beaker). Jumping out of the 
beaker was taken as an indicator of the animal‟s response to heat-induced 
nociceptive pain. The time taken for each mouse to jump out of the beaker (i. e. 
reaction time) was noted and recorded. Capsaicin extract and CPF were tested at 
doses of 0.50, 1.0, 2.0, 4, and 8.0 mg/kg i. p., respectively. Treated „control‟ mice 
received MPN (10 mg/kg i. p.), or DIC (100 mg/kg route) only. Due to the effects of 
gastric juice, capsaicin was administered intraperitoneally, a route that ensures 
adequate systemic bioavailability, early onset and satisfactory pharmacological 
activity of the tested agents. 
 
The mean reaction time for each „test‟ mouse was determined and documented 
using a standard stop watch calibrated in seconds. Each mouse served as its own 
control. Thus, before treatment, its reaction time was determined thrice at 1-hour 
intervals. The mean of these three determinations constituted the „initial reaction 
time‟– that is, reaction time before the treatment of the mouse. The mean reaction 
times for all the mice used were pooled to obtain the final, „control‟ mean reaction 
time (t1). Each of the mice in the study was thereafter treated with either CFE or 
CPF. Thirty minutes after treatment with CFE or CPF, the reaction time was again 
evaluated (t2). This value was pooled for the mice used in each treatment group, and 
the final „test‟ mean value for each treatment group was calculated. This final „test‟ 
mean value represented „after-treatment reaction time‟ for each group of treated 
mice. This „test‟ mean value was subsequently used to determine the percentage 
thermal pain stimulus relief or protection, by applying the formula:  
% protection against thermal pain stimulus = Test Mean – Control  Mean X 100/Control Mean                                                                                                                      
                                                                                 = t1 – t2   x 100 / t2  
[Where t1 = the mean „control‟ reaction time, and t2 = mean „test‟ reaction time, 
respectively].  
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4.3.3.   ASSESSMENT OF CFE AND CPF ANALGESIA USING 
‘ACETIC ACID’ TEST METHOD  
 
The „acetic acid‟ test method used in this study was adopted from those described 
earlier by Koster et al, (1959); Williamson et al, (1996); Zakaria et al, (2001); and 
Silva et al, (2003). The mice used were divided into groups of „test‟ and „control‟ 
animals. The treated group had subunits that received CFE and CPF, respectively, 
subdivided into 5 treatment groups of 10 mice each for graded doses of CFE or CPF 
at 0.5, 1, 2, 4 and 8.0 mg/kg (i.p). Group A control mice included an untreated 
group of 12 mice and two positive „control‟ groups of 10 mice each, that were pre-
treated with DIC (100 mg/kg i.p.) and MPN (10 mg/kg i.p.). Each of the untreated 
„control‟, and „test‟ animals was treated with intraperitoneally-administered 0.2 ml 
of 3% v/v acetic acid solution (Koster et al, 1959). Twenty minutes after  pre-
treatment with DIC, a dose of the capsaicin,  or the extract, 0.2 ml of a 3% w/v of 
acetic acid solution was injected intraperitoneally (i. p.) to each of the „treated‟ mice 
(Koster et al, 1959).  
 
The number of writhings (i. e., abdominal contractions and stretches) that occurred 
within the first 20 minutes following acetic acid administration were counted and 
recorded. The recorded numbers of acetic acid-induced writhings (abdominal 
contractions and stretches) that occurred in the CFE-, CPF-, and DIC- pretreated 
mice were compared with those in the „untreated Group A „control‟ mice. This „test‟ 
mean value was subsequently used to determine percentage inhibition to writhing 
response using the formula:  
% inhibition of writhings response= Control Mean – Test Mean X 100/Control Mean                                                                                           
                                                         =     w1 – w2   x 100 / w1    
[Where w1 = mean ‘control’   and w2 = mean „test‟ writhing movements, 
respectively]. 
    
4.3.4.      DATA ANALYSIS  
 
Data obtained were pooled and presented as means (+SEM). Data from „control‟ 
mice were used as baseline values. The mean reaction times to the pain stimulus 
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were recorded and subsequently analysed using a 2-way ANOVA. Wilcoxon and 
Kruskal-Wallis tests were used to assess any differences. Statistical significance was 
obtained by using a double tailed CI of 95%, and a P value of less than 0.05. 
Pearson correlation coefficient was used to assess the activity of the extract 
compared to that of the synthetic capsaicin as shown in Tables 4.1-4.3. 
 
4.4.    RESULTS 
 
4.4.1.   ANALGESIC ACTIVITY 
 
Capsicum frutescens-derived capsaicin extract (0.5–8.0 mg/kg i. p.) produced dose-
dependent and significant (P0.05–0.001) analgesic effects against thermally- and 
chemically-induced nociceptive pain (see Tables 4.1- 4.3). Pretreatment of the mice 
with either CFE or CPF (0.5–5.0 mg/kg i. p.) caused significant (P0.01–0.0002) 
delays in the mean reaction times of the animals to thermally-induced pain. (Table 
4.1). CFE and CPF (0.5-8.0 mg/kg i.p.) also caused dose-dependent and significant 
(P0.05–0.001) reductions in the acetic acid-induced writhes of the mice (Table 
4.2).  
 
4.4.2.   ACTIVITY LEVEL IN MICE 
 
A general observation of the effects of capsaicin on the activities, sleep, pain 
tolerance and mechano-thermal sensation of mice, were noted. These effects were 
dose dependent, and wear off with time. The animals‟ quality of sleep was also 
better. There were initial excitation following injections of capsaicin, but this was 
followed by playful acts within each cohort, followed by calmness. These occur for 


















4.5          DISCUSSION 
 
Vanilloid 1 receptor has been described as the molecular integrator of several 
nociceptive stimuli (Ferreira et al., 2004). Most studies have alluded to the 
effectiveness of capsaicin-induced central analgesia. The present study aimed to 
explore the potential benefits of capsaicin in both central and peripheral analgesia.  
 
The use of „acetic acid‟ test method to investigate peripheral analgesic mechanism 
was validated at different times by Koster et al., (1959); Williamson et al, (1996); 
Zakaria et al., (2001); and Silva et al., (2003). Similarly, the evaluation of central 
analgesic mechanism using the „hot plate‟ test method was validated by Eddy and 
Leimback, (1953); Lanhers et al., (1992); and Williamson et al., (1996). The 
reduction in the writhings of the abdominal wall and the prolongation of the mean 
reaction time to thermal pain can be regarded as indicative of positive peripheral 
and central analgesic mechanism, respectively.  
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Centrally acting neuromediators can be classified into excitatory and inhibitory 
neuromediators. Glutamate and aspartate are examples of excitatory amino acids 
acting as neurotransmitters centrally. Substance P (SP), calcitonin-gene-related 
peptide (CGRP) and growth factors (e.g., brain derived neurotrophic factors) are 
other examples (Cervero, 1983; Chiang, et al., 1997, and 1999). Inhibitory 
neuromediators include endogenous opioids, such as enkephalin and -endorphins. 
Others are gamma aminobutyric acid (GABA), glycine and -adrenergic agonists. 
The effects of capsaicin at the GABAergic terminals, central MAO receptors, 
NMDA, acetylcholine and noradrenergic receptor sites were earlier elucidated 
(Davis, 1995; Davis, 2000; Woolf, 2000; 2001). The finding suggests that capsaicin 
activity at vanilloid receptors results in analgesia and cerebral depression at low 
doses, and that it produces paradoxical effects at other dissimilar receptors at high 
doses (Davis and Marinelli, 1993; Ralevic, 2001). 
 
The aberration of inflammation and neuropathic enhancement of pain perception as 
seen in allodynia (painful touch) and hyperalgesia are due to increased release of SP 
from the substantia gelatinosa. This phenomenon is called peripheral sensitization, 
and three principal neurotransmitters (NMDA, GABA, and Substance P) have been 
implicated in previous studies. Conversely, any agent acting on these receptors and 
neuromediators have the ability to modulate pain (Wallace, 1997). 
 
Capsaicin showed a potent analgesic potential in the animals used. The explanation 
for the statistically often less significant effects at lower doses might have to do 
with the release of Substance P, due to de-vesiculation mechanism of receptor 
modification, receptor up-regulation and internalization (Yakish, 1999). 
 
     One of the findings of this study is that capsaicin has statistically significant 
(P<0.002) analgesic effects, especially for chronic therapy on centrally-mediated 
pain mechanisms. Peripherally-induced analgesia is statistically significant (P< 
.001) as compared to the „control‟ at P<0.5. This finding probably suggests that 
capsaicin inhibits the inflammatory limb of pain mechanisms, or do so by receptor 
modification, and/or by the „wind-up‟ mechanisms shown in previous studies 
(Winter, 1995). 
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The present study also shows that capsaicin has dose-dependent and statistically 
significant analgesic effects on mechano-thermal and chemically-induced pain.  
These results corroborate earlier studies that capsaicin is efficacious in neuropathic 
pain from diabetes, herpes, phantom and stump pain, chronic pain from 
osteoarthritis, and trigeminal neuralgia (Deal, 1991; Dray, 1990; 1992; Dini, 1993; 
Winter, 1995).  
 
Furthermore, the stimulant effect of capsaicin results in convulsion and death at 
high doses (Nagy, 1980; 1983; Gade, 1985). Further work will be required to 
elucidate the mechanisms of this paradoxical effect. 
 
 
4.6       CONCLUSION 
 
Both capsaicin and Capsicum frutescens Linn [Solanaceae] fruit aqueous extract 
(CFE) have dose-dependent, statistically significant peripheral and central analgesic 
properties. More studies, however, need to be done towards evolving structural 
changes in their chemistry so as to develop capsaicin analogues adaptable for 
human uses in intractable pain from sports injuries, cancer management, and other 
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    CHAPTER 5 
Anti-inflammatory effect of Capsicum frutescens Linn. [Solanaceae] 
aqueous fruit extract in rats 
 
SUMMARY: The present study investigated the anti-inflammatory property of 
Capsicum frutescens Linn. [Solanaceae] fruit aqueous extract (CFE) in rats. In this 
study, inflammation was induced in the rats‟ hind paw following sub-plantar 
injections of 0.5 ml/kg fresh egg albumin. Sixty rats (250-300 g) were divided into 4 
groups. Group A was the „control‟ (10 ml/kg of 0.9 % saline i.p.) and group B 
consisted of 10 rats that received diclofenac (DIC, 100 mg i.p) as the positive 
„control‟. The circumferences of the rats‟ paws were repeatedly measured at time 
intervals of ½, 1, 2, 4, and 8 hours, respectively. Data obtained were pooled and 
analysed using repeated ANOVA, in a general linear model with the CPSS 
software. Compared to the diclofenac (DIC) group, the degree of inhibition of paw 
oedema by CFE and CPF was statistically significant (P<0.05>0.001), best in the 
first 4 hours of treatment.  
 
5.1.                INTRODUCTION 
 
Current anti-inflammatory agents have unacceptable systemic side-effects. With the 
withdrawal of COX-2 agents such as rofecoxib (Vioxx) (Mandell, 2005; Giaquinta, 
2004; Nelson et al., 2004); bextra, (Scheen, 2004); and the recommendation for a 
strong warning on labels of celecoxib and other remaining COX-2 agents (FDA, 
2005); it is evident that natreceuticals and phytochemicals will be sought after as 
alternative anti-inflammatory and analgesic agents. Prostaglandin inhibitors inhibit 
cyclo-oxygenase enzymes; leukotriene formation and pyrogen release (Capone et 
al., 2003). This makes their use to compromise gastric mucosal integrity and renal 
blood flow, resulting in peptic ulcer, upper gastro-intestinal tract (GIT) bleeding, as 
well as renal failure. 
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Current research reports have shown that capsaicin exhibits various potent 
biological activities following oral or topical administration. These include initial 
hyperalgesia, analgesia, dyspepsia, anti-inflammatory, anti-pyretic and anti-
coagulatory activities. Capsaicin can modulate endocrine and paracrine activities, 
immune responses, as well as gastro-intestinal and cardiovascular functions. 
Chronic inflammatory conditions were found to be associated with an up-regulation 
of Substance P receptors (De et al., 1990; Velazquez et al., 2002). Stimulation of 
transient receptor potential vanilloid 1 results in the activation of nociceptive and 
neurogenic inflammatory responses (Rigoni et al., 2003).   
 
Capsaicin has proved very useful in intractable pain of inflammatory origin, such as 
from osteoarthritis, pruritus, psoriasis, rheumatism, and Complex Regional Pain 
Syndrome (Winter et al., 1995; Woolf, 1998; Yakish 1999; Yoshimura et al., 2000). 
Although Capsicum frutescens is traditionally used for the treatment of „fever‟ 
(inflammation), the mechanism of its action is not well known. 
 
One of the main objectives of this study was to examine if capsaicin of South 
African origin has any anti-inflammatory action. The use of carregenin-induced paw 
oedema to investigate anti-inflammatory properties of pharmacological substances 
has been reviewed by Winter et al., (1962) and cited by Winter et al. (1995). The 
increase in paw size following injection of carregenin, or egg albumin as a 
phlogistic agent, is regarded as indicative of inflammation (Ojewole, 2002; 2004; 
Saidu et al, 2000). The degree of inflammation is the difference between the initial 
paw size and the paw size at a chosen time interval. The percentage inflammation is 
thereafter calculated.  The serum C - reactive protein (CRP) level was used to 
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5.2.                       MATERIALS AND METHODS 
 
5.2.1.      FRESH EGG ALBUMIN-INDUCED PAW  
                           OEDEMA IN RATS 
 
Adult rats of both sexes weighing 250-300 g were randomly selected into 4 groups 
(A-D) of 10 rats per group. Baseline measurements of the circumferences of both 
the right and left hind limbs were obtained. 
  
Each rat in the control Group A received 10 ml/kg i.p. of normal saline, while each 
rat in Group B received 100 mg/kg diclofenac (i.p.), respectively. Groups C and D 
rats received 2.5 mg/kg CFE and CPF, respectively. Each of the 40 rats was then 
subjected to inflammation by injecting fresh egg albumin (0.5 ml/kg) into the sub-
plantar of the right paw according to standard protocol. Thereafter, the 
circumferences of the paws were repeatedly measured at time intervals of 30 min, 1, 
2, 4, and 8 hours, respectively.  
 
5.2.2.     BIOCHEMICAL MARKERS OF INFLAMMATION 
 
Blood levels of leucocytes, C-reactive protein and cortisol were measured following 
prolong exposure to both forms of capsaicin and the phlogistic agent by intracardiac 
puncture under intravenous anaesthesia with midazolam („hypnoval‟).  
 
  5.3.                           RESULTS 
 
5.3.1.      FRESH EGG ALBUMN-INDUCED PAW OEDEMA  
 
Sub-plantar injections of fresh egg albumin (0.5 ml/kg) produced profound and 
time-related oedema in the rat hind paw of the „control‟ rats. Plantar swelling and/or 
oedema (which became evident approximately 20-30 minutes following fresh egg 
albumin administration) reached its peak approximately 90 minutes after the sub-
plantar injection of fresh egg albumin.  Diclofenac (DIC, 100 mg/kg) and reference 
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capsaicin (CPF) signficantly inhibited paw swelling at (P0.05–0.001) (CI 95%) 
compared to saline-treated „controls‟. 
 
Table 5.1. Comparative degree of anti-inflammatory effects of capsaicin in rats 
treated with phlogistic agent compared with parallel groups treated with diclofenac 
and saline at the same successive time intervals.  
 
GROUPS Saline Albumin * Alb. + CFE** Alb.+DIC*** Alb. + CPF*** 
%CO/Ct1 94 ± 1 96 ± 1 88 ± 1 86 ± 1 93 ± 1 
%CO/Ct2 97 ± 1 96 ± 1 85 ± 1 83 ± 1 85 ± 1 
%CO/Ct3 100 ± 1 103 ± 1 83 ± 1 80 ± 1 81 ± 1 
%CO/Ct4 100 ± 2 103 ± 1 97 ± 2 95 ± 1 85 ± 1 
%CO/Ct5 102 ± 2 103 ± 2 98 ± 2 96 ± 1 95 ± 1 
 
*P<0.02 ** P<0.001 *** P<0.0001 using repeated ANOVA  
(Where C0= initial paw circumference; C1= paw circumference at 30 min; C2=paw 
circumference at 1 hr; C3= paw circumference at 2 hours; C4= paw circumference 
at 4 hours; C5= paw circumference at 8). 
 
Table 5.2. Comparative degree of anti-inflammatory effects of capsaicin in rats 
treated with diclofenac and saline. 
GROUPS Saline Albumin* Alb. + CFE** Alb.+DIC*** Alb. + CPF*** 
%CO-Ct/C01 -4.1 -0.86 -12.43 -11 -16 
%CO-Ct/C02 -1.98 -0.04 -0.97 -0.6 -21 
%CO-Ct/C03 2.8 0 0.42 -24 -28 
%CO-Ct/C04 3.6 1.43 0.23 -11 -8 
%CO-Ct/C05 3.7 4.31 2.5 -5 -4 
**P<0.001.  *** P<0.0001. (Using repeated ANOVA at 95% CI)                                              
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5.3.2.    CAPSAICIN AND CHEMICAL MARKERS OF   
             INFLAMMATION 
 
Corticosterone levels were all very low (28-31 µmol/L) in 7 rats treated with 
capsaicin. Leucocytes count was within normal range (2.8-11.8 x 10
6
/L) in 11 rats 
due to the innate immunity of the animals, and their intact defence mechanisms. In 
16 specimens randomly assigned for CRP levels, there were very high readings, up 













Alb. +Ref. capsaicin  
Alb. & Diclofenac 
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Table 5.3. C-reactive protein (CRP) levels. 
     
5.4.                  DISCUSSION 
 
The association of vanilloid receptors with inflammation and pain has been 
reviewed (Winter et al, 1995). It has been established that inflammation is a final 
pathway in chronic pain, connective tissue diseases, and various systemic disorders. 
With increase in the levels of Substance P in inflammatory and neurogenic joint 
diseases (arthritis), topical or intra-articular injections of capsaicin have shown a 
significant improvement, as well as reduction in the level of inflammatory 
mediators (Winter et al, 1995; Woolf, 1998; Yakish, 1999; Yoshimura et al, 2000).  
 
Perkins and Campbell (1992) used 6 mg/kg of intra-articular capsaicin to reverse 
mechanical hyperalgesia for several hours. In rheumatoid arthritis, the findings are 
mixed. While Deal and co-workers  (1991) showed significant reduction in the level 
of pain intensity in 31 patients with rheumatoid arthritis of the knee following 
treatment with Zostrix as 0.025% for 4 weeks, McCarthy and McCarty (1992; 1994) 
did not observe improvement in 7 patients with rheumatoid hands using 0.75% 
capsaicin. However, Menkes et al. (1993) reported that application of capsaicin 
(0.75%) for 6 weeks produced a reduction in inflammatory mediators, including 
Substance P, in the synovial fluid of patients with rheumatoid arthritis. 
 
In osteoarthritis, there is evidence to show an increase in the level of Substance P in 
patients (Marshall, 1990; Mapp, 1994). Furthermore, randomized, controlled trials 
have shown significant improvements in pain relief following treatment with 
capsaicin cream. In addition, a double blind trial (Ellis, 1993) showed that capsaicin 
is useful in psoriasis. Post-operative use of capsaicin to prevent upper airway 
 CRP 
uml/L 
Gp A % 
increase 
CRP 
Gp  B % 
increase 
CRP 
Gp  C % 
increas
e CRP 
Gp  D % 
increas
e CRP 
Control 2.5± .2  0  0  0  0 
Rats  15±1 500±46 15±1 512±50  0  0 
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obstruction following Ear, Nose and Throat surgery was recently reviewed (Sicuteri 
1989; Kowalski, 1999). 
 
Studies in humans have shown that pain of inflammatory origin, such as neuropathic 
pain (Wallace, 1997);  post-herpetic neuralgia (Berring, 1990; Kurkccuoglu, 1990; 
Lee, 1994;  Leis et al 2003); complex regional pain syndrome type I (Sicuteri, 
1989); trigeminal neuralgia (Fusco, 1991); oral neuropathic pain (Epstein, 1994); 
cluster headache (Santiciolli, 1987; Maggi, 1988); fibromyalgia (Marks, 1993), in 
acute or chronic conditions, such as osteoarthritis (McCarty, 1994) and rheumatoid 
arthritis (Deal, 1991), have been managed successfully with capsaicin. 
 
In addition, capsaicin has been shown to relief pruritus in patients with psoriasis 
(Ellis, 1993); brachioradial pruritus (Goodless and Eaglstein, 1993); aquagenic 
pruritus (Goodless and Eaglstein, 1993); notalgia parasthetica, nodular prurigo, and 
pruritus produced in patients on haemodialysis (Brand, 1987). In human volunteers, 
capsaicin treatment inhibited itch after histamine and allergen challenge. Itching is 
mediated by a subset of capsaicin-sensitive nociceptive neurons. Blockade of C- 
fibre conduction suppresses itching (Lou, 1992). 
 
Although several studies have alluded to the usefulness of capsaicin in the above 
clinical scenarios, these studies lack statistical or clinical significance. Neither was 
capsaicin compared with placebo or positive controls. In the present study, capsaicin 
was compared to placebo (negative „control‟ saline), and positive controls 
(diclofenac and morphine) respectively. 
 
Statistical significance was found in animals that received diclofenac, CPF and 
CFE, compared to animals in albumin and saline alone groups, respectively. 
Diclofenac, CFE and synthetic capsaicin groups showed significant inhibition of 
inflammation. With regard to the biochemical inflammatory markers, the high CRP 
levels showed that the phlogistic agent induced inflammation in rats. The only 
plausible explanation for the low cortisol levels in all the randomly-sampled animals 
is that CFE and CPF inhibited the unnecessary stress responses, while not inhibiting 
the beneficial pro-inflammatory activities to defend the body from infection. This 
 96  
hypothesis tends to suggest that capsaicin could play a useful role in stress reduction 
and inflammation. 
 
5.5.   CONCLUSION 
 
This study shows that capsaicin possesses dose-dependent anti-inflammatory 
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CHAPTER 6 
 
Pharmacological effects of capsaicin on gastrointestinal smooth 
muscles  
SUMMARY: The present study investigated the effects of increasing 
concentrations of capsaicin, acetylcholine and other agonist drugs, with specific 
antagonists, on strips of chick oesophagus, guinea-pig ileum, and rabbit duodenum. 
The results of this in vitro laboratory animal study indicate that relatively ratio low 
concentrations of CPF (20-40 g/ml) produced significant (p0.05) and 
concentration-related inhibitions of acetylcholine (0.1-5 g)-induced contractions of 
the chick oesophagus, guinea-pig ileum and rabbit duodenum. Biphasic effects 
which were noticed at lower concentrations (0.1-10 ug/ml) were then followed by 
longer-lasting relaxations and/or reductions of the contractile amplitudes of the 
muscle preparations.  
 
6.1.   INTRODUCTION 
 
Substance P (SP) and neurokinin A (NKA) are putative neurotransmitters that exert 
important physiological functions in both the central nervous system and peripheral 
tissues (Bartho et al., 1985).  Renzi et al., (2000) defined the cellular sites of 
Substance P (NK-1R) and neurokin A (NK-2R) receptor expressions in healthy and 
inflamed human intestines by in situ hybridization and immunohistochemistry. The 
investigations observed that they are located in the muscularis mucosae propria and 
lamina propria. In inflammatory bowel diseases, such as Crohn‟s disease and 
Ulcerative colitis, there is an up-regulation of the NK-1R receptors. Both 
tachykinins were found to be co-localized in secretory vesicles. They are co-
released on application of depolarizing stimuli, and when intestinal motility is 
reflexly activated (Donnerer et al., 1984). 
 
Receptors for Substance P have seven transmembrane spanning sequences, and are 
G-protein coupled via the phosphoinositide-signalling pathway (Sasai et al., 1989; 
Hershy et al., 1990; Takahashi et al., 1992; Nakanishi et al., 1991; Guard et al., 
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1991). Within the gastro-intestinal tract, SP and NKA are involved in the 
physiological control of several digestive functions, including motility, fluid and 
electrolyte secretion, blood flow, and tissue homeostasis (Otsuka, 1993; Holzer et 
al., 1997). Consistent with this finding, an upsurge of SP in irritable bowel 
syndrome (IBD) was confirmed by Mantyh et al, (1988). Pretreatment of rats with 
either capsaicin or NK-1R antagonists dramatically reduced fluid secretion, mucosal 
permeability, and intestinal inflammation in animal models of acute and chronic 
inflammation (Castagliuolo et al, 1997; McCafferty et al, 1994; Mantyh et al, 1985; 
Pothoulakis et al., 1994). On this note, selective antagonists of SP have been 
developed for experimental treatment of the triad of diarrhoea, pain, and mucosal 
inflammation.  
The primary aim of this study was to investigate the effects of capsaicin on isolated 
smooth muscles of the chick oesophagus, guinea-pig ileum, and rabbit duodenum. 
Other objectives included elucidation of the possible mechanisms of action of 
capsaicin on smooth muscles as reported in the body of literature, and those findings 
which were not documented as for studies on chick oesophagus, rabbit duodenum 
and guinea-pig ileum. Furthermore, a part of the objectives was to confirm or refute 
any commonly-reported adverse effects of capsaicin. For example, gastro-intestinal 
disturbances through its effects on the locomotor organ of the gastro-intestinal 
smooth muscles.  
 
6.2.     MATERIALS AND METHODS 
 
6.2.1.       ANIMALS 
Young adult, white albino rabbits of both sexes (1.5-3.0 kg), male and female, 
young adult Dunkin-Hartley guinea-pigs (300–450 g); and young chicks (aged 
between 3 and 10 days after hatching (20–40 g) were used. The animals were kept 
and maintained under standard laboratory conditions of light, temperature, and 
relative humidity. The animals were fed with standard pellet diet and drinking tap 
water ad libitum.  
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6.2.2.    EFFECTS OF CAPSAICIN ON CHICK SOLATED      
               OESOPHAGUS 
 
Young chicks (aged between 3 and 10 days after hatching) were starved overnight 
(to empty their crops) and killed by ether inhalation. The upper oesophagus, as far 
as the crop, was carefully isolated together with as much as possible of the right 
parasympathetic nerve trunk which runs along the course of the jugular vein. 
Parasympathetic-innervated oesophageal muscle strips were removed from the 
chicks according to the method described by Bowman and Everett (1964). In each 
case, tubular segments (3–4 cm long) of the entire upper oesophagus were removed, 
set-up, treated and chemically stimulated under physiological conditions as 
described in detail earlier by Ojewole (1976). Each isolated oesophageal muscle 
strip was suspended in a 30-ml „Ugo Basile Organ-Bath‟ containing Krebs-
Henseleit physiological solution (of composition, in g/litre: NaCl, 6.92; KCl, 0.34; 
NaH2PO4, 0.15; NaHCO3, 2.1; MgCl2, 0.11; CaCl2, 0.26; and glucose, 1.00). The 
physiological solution was maintained at 321
o
C and continuously aerated with 
carbogen (i. e., 5% carbon-dioxide + 95% oxygen gas mixture). Two muscle 
preparations (one used as „control‟ and the other one used as CFE or CPF or drug-
treated „test‟ preparation) were always set-up to allow for changes in the 
oesophageal muscle sensitivity. Each preparation was subjected to a resting tension 
of 1.0 g, and allowed to equilibrate for 30–45 minutes before it was challenged with 
CFE or CPF, and other drugs used. Concentrations of CFE or CPF (and other drugs 
used) were added to the bath-fluid either cumulatively or sequentially (i.e., non-
cumulatively), and washed out three-to-five times after the maximum responses of 
the tissues were attained. Concentrations of bath-applied CFE or CPF (and other 
drugs used) were repeated where appropriate and/or possible, at regular intervals of 
20–30 minutes after the last washing. The electrically-induced contractions, as well 
as CFE or CPF and other drug-induced responses of the muscle preparations were 
recorded isometrically by means of Ugo Basile force-displacement transducers and 
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6.2.3.      EFFECTS OF CAPSAICIN ON GUINEA-PIG       
                  ISOLATED     ILEUM 
 
Male and female Dunkin-Hartley guinea-pigs (weighing 300–450 g) were used. 
Each of the animals was killed by deep ether inhalation and bled out. Tubular pieces 
(3–4 cm long) taken from distal ileum of each animal were suspended in 30-ml 
„Ugo Basile Organ-Baths‟ (model 4050) containing Krebs-Henseleit physiological 
solution maintained at 361
o
C and continuously aerated with carbogen (i. e., 5% 
carbon-dioxide + 95% oxygen gas mixture). Two ileal muscle preparations (one 
used as „control‟ and the other one used as capsaicin- or drug-treated „test‟ 
preparation) were always set up to allow for changes in the ileal muscle sensitivity. 
The tissues were subjected to a resting tension of 1.0 g, and allowed to equilibrate 
for 30–45 minutes before they were challenged with concentrations of CFE or CPF 
(or other drugs used). Concentrations of capsaicin (and other drugs used) were 
added to the bath-fluid either cumulatively or sequentially, and washed out three-to-
five times after the maximum responses of the tissues were attained. Concentrations 
of capsaicin (and other drugs used) were repeated where appropriate and/or 
possible, at regular intervals of 20–30 minutes after the last washing. CFE or CPF - 
(and other drugs-) induced contractions and responses of the isolated ileal muscle 
preparations were recorded isometrically by means of Ugo Basile‟s force 
displacement transducers and 2-Channel “Gemini” Recorders (model 7070).   
 
6.2.4.   EFFECTS OF CAPSAICIN ON RABBIT ISOLATED  
               DUODENUM 
 
Each rabbit used was killed by deep ether inhalation and bled out. The abdomen of 
the animal was quickly opened by a midline incision, and tubular pieces (3–4 cm 
long) of the duodenum were carefully cleaned free of connective, extraneous and 
fatty tissues, and then removed. The tubular pieces (3–4 cm long) were separately 
suspended in 30-ml „Ugo Basile Organ-Baths‟ (model 4050) containing Krebs-
Henseleit physiological solution maintained at 361
o
C and continuously aerated 
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with carbogen (i. e., 5% carbon-dioxide + 95% oxygen gas mixture). Two isolated 
duodenal preparations, one used as „control‟ and the other one used as CFE or CPF 
or drug-treated „test‟ preparation were always set-up to allow for changes in the 
duodenal muscle sensitivity. Each of the isolated duodenal muscle preparations was 
allowed to equilibrate for a period of 30–45 minutes under an applied resting 
tension of 1.5 g, before it was challenged with concentrations of CFE or CPF and 
other drugs used. Concentrations of CFE or CPF and other drugs used were applied 
to the bath-fluid either cumulatively or sequentially, and washed out three-to-five 
times after the maximum responses of the tissues were attained. Concentrations of 
CFE or CPF and other drugs used were repeated where appropriate and/or possible, 
at regular intervals of 20–30 minutes after the last washing. The amplitude and 
frequency (rate) of the spontaneous, myogenic, pendular, rhythmic contractions, as 
well as the CFE or CPF and other drug-induced responses of the isolated muscle 
strips were recorded isometrically with the aid of Ugo Basile force-displacement 
transducers and 2-Channel “Gemini” Recorders (model 7070).   
 
 
6.3.           DATA ANALYSIS  
 
Data obtained from „test‟ groups of isolated muscle strips (chick oesophagus, 
guinea-pig ileum, and rabbit duodenum) treated with CFE or CPF and other drugs 
used, and those obtained from saline-treated „control‟ isolated muscle preparations, 
were pooled, and expressed as means (SEM). The differences between CFE or 
CPF or drug-treated „test‟ means, and saline-treated „control‟ means, were analyzed 
statistically by using „Student‟s t-test‟ (Snedecor and Cochrane, 1967) to determine 
the level of significance of the differences between the „test‟ and „control‟ group 
data means. Values of P0.05 were taken to imply statistical significance.  
 
6.4.      R E S U L T S 
 
The results obtained in this set of experiments demonstrated that CFE or CPF 
possesses an array of pharmacological actions on extra-vascular (i. e., non-vascular) 
smooth muscles, and confirm the findings of the previous workers. 
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6.4.1. EFFECTS OF CAPSAICIN ON CHICK ISOLATED      
         OESOPHAGUS 
Relatively low to high concentrations of CFE or CPF (5–160 g) always produced 
initial brief rises in the baseline tensions of the the chick oesophageal muscle 
preparations in a concentration-dependent manner. Furthermore, relatively small to 
high concentrations of CPE or CPF (5–160 g) always produced a secondary 
concentration-related and significant (P0.05), inhibitions of the chick oesophageal 
muscle preparations. Figures 6.1 summarize the results obtained. Acetylcholine 
(ACh)-provoked contractions of the chick oesophageal muscle preparations were 
concentration-dependently inhibited or abolished by bath-applied atropine (0.1–2.5 
g/ml) similar to 1-2 g/ml of CFE or CPF (Figure 6.1). 
 
 
Figure 6.1a. Shows a typical trace obtained following escalated concentrations of 
CPF on chick oesophagus. CPF 1-6 represents capsaicin 5, 10, 20, 40, 80, and 160 
µg/ml, respectively. 
 CPF   ●    ●   ●   ●   ●  ● 
          1     2    3   4   5  6 





Figure 6.1b. Shows CPF concentration-effect curve following escalated 
concentrations of CPF on chick oesophagus. 
 
 
Figure  6.1c. Shows concentration-effect curve to acetylcholine (ACh) in the 
absence and in the presence of CPF (20 µg/ml and 40 µg/ml, respectively) on the 
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Figure 6.1d. Shows concentration-effect curves to acetylcholine (ACh) in the 
absence, and in the presence, of CPF (20 µg/ml and 40 µg/ml respectively) on the 
chick oesophagus. * P< 0.05 ** P< 0.01. 
 
6.4.2.     EFFECTS OF CAPSAICIN ON GUINEA-PIG ISOLATED   
ILEUM 
 
In the guinea-pig isolated ileal muscle preparations, the pharmacological effects of 
relatively low to high concentrations of CFE or CPF (5–160 g/ml) were found to 
be similar to those produced by the plant‟s extract in the chick-isolated oesophageal 
muscle preparations. However, relatively low to high concentrations of CFE or CPF 
10–160 g/ml) always raised the baseline tension (baseline tone) of, and contracted 
the guinea-pig isolated ileal muscle preparations in a concentration-dependent 
manner. Acetylcholine (ACh, 0.1–2.5 g/ml), and carbachol (1.0–10.0 g/ml), also 
contracted guinea-pig isolated ileum in a concentration-related manner. Relatively 
low to high concentrations of CFE or CPF (10–160 g) potentiated acetylcholine-
(ACh, 0.1–1.0 g/ml)-induced contractions of guinea-pig isolated ileum in a 
concentration-related manner. Like acetylcholine and carbachol-provoked 
contractions of the guinea-pig ileal muscle preparations, CFE or CPF contractions 
of the guinea-pig isolated ileal muscle preparations were also concentration-
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Figure 6.2a. Shows concentration-effect curves to acetylcholine (ACh) in the 
absence, and in the presence, of CPF (20 µg/ml and 40 µg/ml respectively) on 
isolated guinea-pig ileum. * P< 0.05 ** P< 0.01 
 
 
Figure 6.2b. Shows concentration-effect curves to acetylcholine (ACh) in the 
absence, and in the presence, of CPF (20 µg/ml and 40 µg/ml respectively) on 
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Figure 6.2b. Shows concentration-effect curves to acetylcholine (ACh) in the 
absence, and in the presence, of CPF (20 µg/ml and 40 µg/ml respectively) on 
isolated guinea-pig ileum. 
 
CPF   ● ● ● ● ● ●
1     2    3   4   5  6
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Figure 6.3. Shows a typical trace obtained following escalated concentrations of 
CPF on isolated guinea-pig ileum.  CPF 1-5 represents capsaicin 5, 10, 20, 40, 80, 
and 160 µg/ml, respectively. 
 
Figure 6.4. Shows concentration-effect curve to capsaicin (CPF) in the absence, and 
in the presence, of 20 ug/ml atropine (ATR) on isolated guinea-pig ileum. * P< 0.05  
 
 
Figure 6.4a.1. Shows a typical trace obtained following CPF (10µg/ml) on isolated 
guinea-pig ileum.  CPF (10µg/ml) was added to the bath-fluid at the left hand-side, 
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Figure 6.4a.2. Shows typical trace obtained following CPF (20 µg/ml) on isolated 
guinea-pig ileum. CPF (20 µg/ml) was added to the bath-fluid at the left hand-side, 
upward-pointing arrow, and washed off 4-5 times at the adjacent, right hand-side, 
downward-pointing arrow. 
 
Figure 6.4a.3. Shows typical trace obtained following CPF (40 µg/ml) on isolated 
guinea-pig ileum. CPF (40 µg/ml) was added to the bath-fluid at the left hand-side, 
upward-pointing arrow, and washed off 4-5 times at the adjacent, right hand-side, 
downward-pointing arrow. 
CPF ● ●   
        ↑ ↓ 
CPF ●  ● 
         ↑  ↓ 
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6.4.3.    EFFECTS OF CAPSAICIN ON RABBIT ISOLATED                      
               DUODENUM 
 
Relatively low to high concentrations of CFE or CPF (10–160 g/ml) usually 
induced concentration-related, biphasic responses in rabbit isolated duodenum. 
These initial inhibitory effects of CFE or CPF were always followed by sharp, 
significant (P0.05–0.001) increases in the baseline tones (baseline tensions) of the 
muscle preparations. The increases in contractile amplitudes and baseline tones of 
the rabbit duodenal muscle preparations were oftens followed by gradual, 
concentration-dependent, secondary, longer-lasting, significant (P0.05–0.001) 
reductions in the amplitudes of the isolated muscle strips (Figure 6.5). The 
secondary effects of CFE or CPF were resistant to blockade by standard, receptor 





Figure 6.5a.1. Shows a typical trace obtained following CPF (10 µg/ml) on rabbit 
isolated doudenum. CPF (10 µg/ml) was added to the bath-fluid at the left hand-
side, upward-pointing arrow, and washed off 4-5 times at the adjacent, right hand-
side, downward-pointing arrow. 
 
CPF   ● ●    
          ↑ ↓ CPF●  ● 
       ↑  ↓ 
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Figure 6.5a.2. Shows a typical trace obtained following CPF (20 µg/ml) on rabbit 
isolated duodenum. CPF (20 µg/ml) was added to the bath-fluid at the left hand-
side, upward-pointing arrow, and washed off 4-5 times at the adjacent, right hand-
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Figure 6.5a.3. Shows typical trace obtained following CPF (40 µg/ml) on rabbit 
isolated duodenum. CPF (40 µg/ml) was added to the bath-fluid at the left hand-
side, upward-pointing arrow, and washed off 4-5 times at the adjacent, right hand-








Figure 6.5a.4. Shows a typical trace obtained following CPF (80 µg/ml) on rabbit 
isolated duodenum. CPF (80 µg/ml) was added to the bath-fluid at the left hand-
side, upward-pointing arrow, and washed off 4-5 times at the adjacent, right hand-
side, downward-pointing arrow. 
CPF  ●                  ●  
         ↑                  ↓ 











Figure 6.5b. Shows concentration-effect curves to acetylcholine (ACh) in the 
absence, and in the presence, of CPF (20 µg/ml and 40 µg/ml respectively) on 
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Figure 6.5c. Shows concentration-effect curves to acetylcholine (ACh) in the absence, and in the presence, 






6.5.     DISCUSSION 
Relatively low doses of the capsaicin extract caused significant (P0.05) increases 
in the basal tone of chick isolated oesophagus and guinea-pig ileum. High doses of 
the extract increased the basal tone in a biphasic pattern (P<0.05) on the chick 
oesophagus and guinea-pig ileum. Bath-applied acetylcholine (ACh) induced 
concentration-dependent contractions of the isolated muscle preparations. The 
contraction noted at high concentration might be due to general stimulant effects of 
capsaicin through the release of calcium ions. On the other hand, vanilloid receptors 
in the gastro-intestinal tact (GIT) might have been stimulated at high doses. 
The inhibitory effects of CFE or CPF on gastro-intestinal smooth muscles are 
supported by various studies (Bartho, 1985; Bjorkroth, 1983; Borrelli et al., 2004; 
Croci et al., 1994). In addition to inhibitory effects on GIT, El-Mahmoudy (2003) 
showed non-adrenergic, non-cholinergic (NANC) mechanism. Moreover, Goldhill 
(1999) showed that capsaicin has an antisecretory effect on GIT mucosa. The fact 
that capsaicin has inhibitory effect on the GIT is supported by earlier studies by 
Holzer et al., (1992); Jun, (1990); Pothoulakis et al., (1994); and Ralevic, (2001). 
Moreover, Ralevic (2001) related the inhibitory effects of endocannabinoid 
substances to interactions via vanilloid receptors. Indirectly, Robinson et al., (2003) 
showed that Substance P caused early diarrhoea in Cryptococcus infected intestine. 
The precise mechanism of the primary inhibitory effects of the plant‟s extract on 
rabbit isolated duodenal muscle preparation is obscure at the moment. However, 
because the primary inhibitory effects of capsaicin were resistant to blockade by 
standard, receptor-specific antagonists in all the isolated muscle preparations tested, 
it is speculated that the secondary, longer-lasting inhibitory and/or depressant 
effects of capsaicin on rabbit duodenal muscle preparations may be non-specific in 
nature. 
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 Furthermore, the finding that changes (decrease or increase) in calcium ion 
concentrations of the bathing physiological solution modified the responses of the 
isolated tissue preparations to bath-applied concentrations of capsaicin extract 
would appear to suggest that capsaicin affects calcium mobilization and/or 
sequestration, and possibly calcium release from its various tissue stores. Further 
studies are certainly warranted to shed more light on this plausible mechanism of 
action of capsaicin. The finding earlier reviewed by Del et al., (1991), showed the 
different pathways by which extracellular Ca
2+
 promotes calcitonin-gene-related- 
peptide (CGRP) release from central terminals of capsaicin-sensitive afferent 
pathways of guinea-pigs. Furthermore, the resultant effects of extracellular K+ and 
low pH may influence the dialectic nature of the effects of capsaicin on smooth 
muscles. Santiciolli, et al. (1987; 1992) showed the dual nature of capsaicin on 
neuro-effector and contractile tissues based on pH of the tissues. This corroborates 
the work of Bleakman (1992) on the effects capsaicin on dorsal root ganglion cells. 
Olah (2001) has shown that at acidic pH, vanilloid-active agents do effectively 
stimulate vanilloid receptors.  
However, the experimental evidence obtained in the present laboratory animal study 
indicates that capsaicin behaves like a partial agonist, contracting gastro-intestinal 
tract smooth muscles when acting alone, while it inhibits the contractility achieved 
by a pure agonist such as ACh. This observation would appear to provide 
pharmacological basis for the frequently-reported adverse effects of capsaicin on 
gastro-intestinal tract (GIT), viz: discomfort or „upset‟ commonly associated with 
capsaicin at very high doses. 
 
Capsicum frutescence Linn. [Solanaceae] has been reported to be rich in sugars, 
phytosterols, triterpenoids, coumarins, flavonoids and iridoids (Watt and Breyer-
Brandwijk (1962); Van Wyk and Gericke (2002). These chemical compounds could 
have altered the excitability of the GIT smooth muscles used in this study. 
 
The evidence obtained in the present in vitro study further indicates that capsaicin 
possesses biphasic effects on gastro-intestinal smooth muscle contractility. These 
findings appear to provide pharmacological rationale for the use of capsaicin as a 
carminative at therapeutic doses; while high doses may lead to diarrhoea and 
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„abdominal discomfort‟. The gastro-intestinal tract smooth muscle contractile 
effects of capsaicin may be due, through the complex interactions that might occur 
among the various chemical constituents of the plant, to the release of mediators and 
substances that are capable of contracting smooth muscles. Finally, capsaicin may 
have an allosteric site on smooth muscle membranes, close to ACh binding site, 
whose conformational changes, following binding, may lead to release of calcium 




6.6.   CONCLUSION 
 
Capsaicin produces biphasic effects on smooth muscles of the GIT. The effects of 
capsaicin shown in the present study have been reported by many earlier 
investigators. However, the partial agonistic effect of capsaicin on cholinergic 
mechanism is shown for the first time, indicating closely-linked allosteric sites of 























Bartho, L. and Holzer, P.  (1985). Search for a physiological role of Substance P  
               in gastrointestinal motility. Neuroscience.16 (1): 1-32. 
 
Bjorkroth, U.   (1983). Inhibition of smooth muscle contractions induced by      
capsaicin and electrical transmural stimulation by a Substance P  
               antagonist. Acta Physiology Scandinavia Supplement.; 515: 11-16. 
 
Bleakman, D. Brorson, J.R. and Miller, R.J.  (1990). The effects of capsaicin on     
voltage-gated calcium currents and calcium signals in cultured dorsal root 
ganglion cells. British Journal of Pharmacology; 101: 423-431. 
Borrelli, F. Raffaele, C. R. Pinto, A. and Izzo, A.A. (2004). Inhibitory effect of   
             ginger (Zingiber officinale) on rat ileal motility in vitro: Life Sciences; 74     
             (23): 2889-2896.  
Bowman, W.C. and Everett, S.D. (1964). An isolated parasympathetically-   
 innervated oesophagus preparation from the chick. Journal of Pharmacy    
 and Pharmacology; 16 (Suppl.): 72T-79T. 
Castagliuolo, I.  Keates, A.C. Qiu, B. Kelly, C.P. Nikulasson, S. Leeman, S.E. and              
            Pothoulakis, C. (1997). Increased Substance P responses in dorsal root     
       ganglia and intestinal macrophages during Clostridium difficile toxin A     
enteritis in rats. Procedures of National Academy of Science U S A.  29; 94    
(9): 4788-4793. 
 122  
Croci, T. Emonds-Alt, X. and Manara, L. (1994). SR 48968 selectively prevents 
faecal excretion   following activation of tachykinin NK2 receptors in rats. 
Journal of Pharmacy and Pharmacology; 46 (5): 383-385. 
Del, B.E. Santicioli, P. Tramontana, M.  Maggi, C.A. Cecconi, R.and Geppetti, P.  
              (1991). Different pathways by which extracellular Ca 2
+
 promotes 
calcitonin gene-related peptide release from central terminals of capsaicin-
sensitive afferents of guinea-pigs: Effects of capsaicin, high K
+
 and low pH 
media. Brain Research; 566: 46-53. 
 
Donnerer, J. Bartho, L. Holzer, P. and Lembeck, F. (1984). Intestinal peristalsis       
              associated with release of Substance P. Neuroscience; 11: 913-918. 
 
El-Mahmoudy, A, Matsuyama, H. Khalifa, M. Shimizu, Y. and Takewaki, T.     
              (2003). Tachykinins mediate non-adrenergic, non-cholinergic excitatory  
         neurotransmission to the hamster ileum via NK1 and NK2 receptors.  Life      
         Sciences. 29; 73 (15): 1939-1951.  
 
Goldhill, J. Porquet, M.F. and  Selve, N.  (1999). Antisecretory and relaxatory 
effects of tachykinin antagonists in the guinea-pig intestinal tract.  Journal 
of Pharmacy and Pharmacology; 51(9): 1041-1048. 
 
Guard, S.  McKnight, A.T. Watling, K.J. and Watson, S.P. (1991). Evidence for two        
               types of tachykinin receptors on cholinergic neurons of the guinea-pig    
               ileum  myenteric plexus. Annual New York Academy of Science; 632: 
400-403. 
 
 Gyires, K. (2004). Neuropeptides and gastric mucosal homeostasis. Current Topics      
               in Medicinal Chemistry;  4(1): 63-73 (11). 
Holzer, P. (1991). Capsaicin: Cellular targets, mechanisms of action, and selectivity                  
               for thin sensory neurons. Pharmacological Reviews; 43: 143-201. 
 123  
Holzer, P. Lippe, I.T. and Amann, N. (1992). Participation of capsaicin-sensitive      
afferent neurons in gastric motor inhibition caused by laparotomy and    
intraperitoneal acid. Neuroscience; 48: 715-722. 
Holzer, P. and Holzer-Petsche, U. 1997). Tachykinins in the gut. Part I. Expression, 
release and motor function. Pharmacology and Therapeutics; 73: 173-217. 
Holzer, P. and Holzer-Petsche, U.  (1997). Tachykinins in the gut. Part II. Roles in 
neural excitation, secretion and inflammation. Pharmacology and 
Therapeutics; 73: 219-263. 
 Mantyh, C.R. Gates, T.S. Zimmerman, R.P. Welton, M.L. Passaro Jr, E.P. Vigna, 
S.R. Maggio, J.E. Kruger, L. and Mantyh, P.W. (1988). Receptor binding 
sites for Substance P, but not substance K or neuromedin K, are expressed     
in high concentrations by arterioles, venules, and lymph nodules in 
surgical specimens obtained from patients with ulcerative colitis and 
Crohn disease. Procedures of Nationall Academy of Science U S A; 
85(9): 3235-3239. 
Mantyh, C.R. Gates, T. Vigna, S.R. and Maggio, J.E. (1988). Receptor binding sites 
for Substance P and substance K in the canine gastrointestinal tract and 
their possible role in inflammatory bowel disease. Neuroscience; 25 (3): 
817-837. 
McCafferty, D.M. Sharkey, K.A. and Wallace, J.L. (1994). Beneficial effects of 
local or systemic lidocaine in experimental colitis. American Journal of 
Physiology;  266: G560-567). 
Nakanishi, S. (1991) Mammalian tachykinin receptors. Annual Review of 
Neuroscience; 14: 123-136. 
Ojewole, J.A.O. (1976). Studies on the Pharmacology of Some Antimalarial Drugs. 
PhD Thesis, University of Strathclyde, Glasgow.  
Olah, Z. Karai, L. and Iadarola, M.J. (2001). Anandemide activates vanilloid 
receptor 1 (VR1) at acidic p
H
 in dorsal root ganglia neurons and cells 
 124  
ectopically expressing VR1. Journal of Biological Chemistry; 276(33): 
31163-31170. 
Otsuka, M. Yoshioka, K. (1993) Neurotransmitter functions of mammalians 
tachykinins. Physiological Reviews; 73:229-308. 
Pothoulakis, C. Castagliuolo, I. LaMont, J.T. Jaffer, A. O'Keane, J.C. Snider, R.M. 
and Leeman, S.E. (1994). CP-96,345, a Substance P antagonist, inhibits rat 
intestinal responses to clostridium difficile toxin A but not cholera toxin. 
Procedures of National Academy of Science U S A; 91 (3): 947. 
Ralevic, V.  Kendall, D.A. Jerman, J.C. Middlemiss, D.N. and Smart, D. (2001). 
Cannabinoid activation of recombinant and endogenous vanilloid receptors 
l. European Journal of Pharmacology; 424 (3): 211-219. 
Renzi, D. Pellegrini, B. Tonelli, F. Surrenti, C. and Calabro, A.  (2000). Substance P 
(neurokinin-1) and neurokinin A (neurokinin-2) receptor gene and protein 
expression in the healthy and inflamed human intestine. American Journal 
Pathology.; 157(5): 1511-1522. 
Robinson, P. Okhuysen, P.C. Chappel, C.L. Weinstock, J.V. Lewis, D.E. Actor, 
J.K. and White Jr, A.C . (2003). Substance P expression correlates with 
severity of diarrhoea in cryptosporidosis. Journal of Infectious Disease; 15; 
188 (2): 290-296. 
                  
Santiciolli, P. Patacchini, R. Maggi, C.A. and Meli, A. (1987). Exposure to 
calcium-free medium protects sensory fibers by capsaicin desensitization. 
Neuroscience Letters; 80: 167-172. 
 
Santicioli, P. Del Bianco, E. Geppetti, P. and Maggi, C.A. (1992). Release of 
calcitonin gene-related peptide-like   (CRGP-LI) immunoreactivity from 
rat isolated isoleus muscle by low p
H
, capsaicin and potassium. 
Neuroscience Letters; 143: 19-22. 
 125  
Sasai, Y. and Nakanishi, S. (1989). Molecular characterization of rat substance K 
receptor and its mRNAs. Biochemistry Biophysics Research 
Communication; 165: 695-702. 
Takahashi, K. Tanaka, A. Hara, M. and Nakanishi, S. (1992). The primary structure 
and gene organization of human Substance P and neuromedin K receptors. 
European Journal of Biochemistry; 204: 1025-1033. 
Van WYK, B. E. Van Oudtshoom B, Gerickek, N. (2002) Medicinal Plants of South 
Africa (2nd ed.), Briza Publications, Pretoria :156–157.   
Watt, J.M. Breyer-Brandwijk, M. G. (1962). The medicinal and poisonous plants of 




























Effects of capsaicin on coagulation  
 
SUMMARY: This study investigated the effect of capsaicin on coagulation. Ten 
animals in each of three treatment groups received 2.5, 5.0, 10 mg/kg (i.p.) 
capsaicin respectively. Compared to the control group, the mean INR was 
statistically significant (P<0.05). Taken together, the use of capsaicin at therapeutic 
doses (2.5-10.0 mg/kg) may reduce thromboembolism without any clinically 
relevant alteration in platelets.  
 
7.1.     INTRODUCTION 
 
Primary homeostasis is produced by the action of platelets and blood vessels 
(Petrovitch, 2002; Rubin, 2001). Secondary homeostatic mechanism is enhanced by 
the interaction of many plasma proteins known as “clotting factors” in various 
sequence to produce fibrin. Often, specific medications are used to enhance or 
inhibit individual step in coagulation cascade.  Various phytochemicals have been 
shown to interact with these clotting mechanisms (Mohammed, 1986; Ariga, 1981; 
Boullin, 1981; Greuwald, 2000; Yuan 2003; De Smet, 2002). The side-effects of 
uncontrolled use of these herbal remedies could be disastrous from severe bleeding 
episodes (Rose, 1990; Rowin, 1996; Fessenden, 2001); hepatotoxicity (Gebhardt, 
1993), nephrotoxicity, and cardiopulmonary complications (Garges, 1998). 
Capsicum spp. constitutes a part of the oldest herbal medications known for more 
than 5000 years. Some of the beneficial effects of Capsicum spp. include anti-
tumour and calminative effects, as well as their usefulness in the treatment of acute 
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and chronic pain (Weil, 1981). Recent study by Jaiarj et al. (1998) found that 
capsaicin acting on the heat sensitive vanilloid receptors had thrombolytic effects. 
Although this was a comment on the review of cardiovascular effects of capsaicin, 
the evidence was not strong enough. Jaiarj et al. (1998) also observed that 
individuals who consumed a large amount of Capsicum have lower incidence of 
thromboembolism. The objective of this study was to investigate the coagulatory 
benefits of capsaicin, which is the active vanilloid-sensitive agent in Capsicum spp.  
 
7.2.           MATERIALS AND METHODS 
 
7.2.1.       ANIMALS 
 
Experiments were performed on male Wistar rats (250-300 g). The rats were 
maintained under standard laboratory conditions of light, temperature, and relative 
humidity. The animals were fed with standard diet pellet and drinking tap water ad 
libitum and kept in the Biomedical Resource Unit of the University of KwaZulu-
Natal, Durban.  
 
 
7.2.2.       HAEMATOLOGICAL TESTS FOR COAGULATION  
                         
In a pilot study, 10 Wistar rats (250-300 g) had oral treatments of 50 mg/kg of 
Capsicum frutescens fruit extract (CFE). The tissue‟s morphology was examined 
grossly from the oesophagus to the intra-abdominal organs. 
 
In the definitive study, Witstar rats weighing 250–300 g were divided into two 
groups (A and B) of control and treated animals. They had similar demographics in 
terms of sex, age, and weight. All the animals were fed with standard diet pellet and 
drinking tap water ad libitum. Group A consisted of 10 untreated animals which 
served as controls. Group B consisted of 3 treatment groups of 10 animals per 
group, treated with CFE, 2.5, 5.0, or 10.0 mg/kg i.p., respectively. Following 
treatment, 1.5-2 ml blood was collected by intracardiac puncture, following deep 
halothane anaesthesia. The blood specimens were analysed for their platelets, as 
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well as the internationalised normalised ratio (INR) of prothrombin.  In a parallel 
study, 3 groups of 10 Wistar rats per group were treated with 8 mg/kg of capsaicin 
extract daily for 2 weeks. From each animal, 2 ml of blood was collected by 
intracardiac puncture, following deep halothane anaesthesia.  The specimens were 
analysed for urea and creatinine.  
 
 
7.3.                   RESULT 
 
The results obtained show dose- and time-independent variations of INR in the 
treated groups, compared to the controls. The difference mean INR between the 
treated groups was statistically significant (p<0.05), showing INR of 1±0.1, 1.4±0.1 
and 2.0±0.3, respectively, for the treated groups of CFE, 2.5, 5.0 and 10 mg/kg, 
respectively. Earlier pilot study showed macroscopic evidence of erosion, mucosal 
oedema, bleeding and ulceration, following oral administration of capsaicin extract 
at 50 mg/kg. In parallel studies, capsaicin did not show any renal complications in 
rats that were exposed to capsaicin treatments at therapeutic doses (8 mg/kg) daily 
for 2 weeks. The mean urea and creatinine were 5.4± 0.3mmol/L and 45±1 umol/L, 
respectively, in the rats. 
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Figure 7.1. Shows dose-related increase in INR from 5-10 mg/kg i.p.capsaicin 
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Figure 7.3. Arrow showing gastric ulceration from chemical burns following 50 




7.4.   DISCUSSION  
 
For a medication to impact on coagulation, it has to affect the Virchow‟s triad of the 
blood vessel, blood flow and blood viscosity (Virchow, 1856 and 1858, Brotman, et 
al., 1981). The flow is influenced by the rheology of blood and the container. 
Considering Newtonian fluids, Fung reviewed the various factors influencing flow 
as represented below: 
Flow Rate = (p1-p2) x d
4 
x π /128 x l x ŋ   (Fung, 1993) 
Where p1= pressure at the entry of a vessel, p2 = pressure at the exit of a vessel, and 
d
4 
= double square of the diameter of the vessel, p1-p2 = pressure gradient across a 
vessel, l = length of the vessel and the viscousity of the Newtonian fluid.
            
Considering this mathematical relationship, one will discover the interaction of the 
inner and the external diameters of the vessel, the pressure gradient in the flowing 
liquid, length of the vessel as well as the viscosity on the flow. To flow, the fluid 
has to overcome a resistive force, which is twice as great as the diameter of the 
vessel and frictional forces produced by viscosity. Although blood is a non-
Newtonian fluid, the role of viscousity as well as vessel narrowing in the capillary 
and other microcirculation, is essential for the processes of diapedesis and platelet 
plugging in homeostasis (Chin, 2001; Byung, 1990). The platelets, microaggregates 
from white corpuscles and clotting factors, could be viewed as responsible for the 
viscousity, the pressure head being provided upstream by peripheral vascular 
resistance and the central pump of the heart, while the length and consistency of 
vessel calibre greatly relate the other variables in the formula. For capsaicin to 
affect coagulation, it has to influence one or more of the three notable variables of 
the triad, i.e., the flow, the vessel or the constituents. 
The role of capsaicin in the flow of blood has not been substantiated. Available 
evidence suggests that it may cause vasodilation, presenting as „goose flesh‟ in 
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Wistar rats following i.p administration. Jaiarj et al., (1998) also observed that 
capsaicin does increase platelet adhesion. It is debatable if this increase is 
statistically or clinically significant. Furthermore, the effects of capsaicin on clotting 
factors have received inconclusive evidence. 
 
The standard methods of coagulation monitoring include measurements of bleeding 
time, protrombin time (PT), or the measurement of Internationalised Normalised 
Ratio (INR). Bleeding time is the best estimate for platelets‟ qualitative function, 
but it lacks correlation with clinical bleeding, hence, the little value with its use. In 
addition, bleeding time estimates may be more difficult to assess in laboratory 
animals. But platelets count is useful for the estimation of quantitative function. 
However, the quantitative estimation of platelets has little to do with the function of 
platelets. The PT and INR are useful to estimate extrinsic and common pathways. 
The intrinsic and common pathways can be assessed by the partial 
prothromboplastin time (PTT), activated partial thromboplastin time (aPTT), and 
the activated clotting time. For the purpose of this study, the platelets counts, as well 
as the INR, were used as tests of extrinsic and common pathways. Intraperitoneal 
administration of capsaicin without any direct or intrinsic vessel injury was 
expected to affect intrinsic pathway, the extrinsic pathway, and the common 
pathway in a similar manner; hence the use of common indicators such as the 
platelets count and the INR. 
 
The results obtained in this study show that platelets number was within normal 
range in the „test‟ animal groups. Although platelet adhesion was found in the study 
by Jaiarj et al., (1998), the present investigation could not document any platelet 
clumping, rouleax formation or any increased adhesion in the „test‟ animal groups. 
However, the trend of INR in the animals showed dose-dependent increase. This 
may reflect the tendency for capsaicin to influence the clotting factors through the 
common pathway, or the extrinsic coagulatory pathway. However, there have been 
reports of capsaicin affecting the release of Hageman factor-calcium. Calcium is a 
rate-limiting catalyst at various phases of coagulation (Stoelting et al., 2002). 
 
The discussion on coagulation and anti-platelet activity cannot be laid to rest 
without considering the role of prostaglandins in renal and gastro-intestinal 
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functions. Inhibition of prostaglandin in the stomach and the kidneys has led to 
gastric ulcer or haemorrhage, and nephrotoxicity. This is because prostaglandin is a 
modulator of gastric mucosal blood flow, and it is important for the maintenance of 
renal glomerular blood flow. Although INR is prolonged by capsaicin, renal 
function in a parallel study remained normal following prolong exposure to 
capsaicin. 
 
The effect of capsaicin on coagulation provides alternate non-antiprostagladin 
mechanisms of thromboprophylaxis without the inherent nephrotoxicity and 
gastropathy common with most currently-used antithrombotic anti-platelet agents at 
therapeutic doses. Alternative non-oral and parenteral routes might improve the 
side-effect profile of capsaicin by the use of subcutaneous, intramuscular, or as 
enteric-coated capsules. The exact factor, or plasma proteins altered in the 
coagulatory cascade by capsaicin is beyond the scope of the present study. 
 
7.5.              CONCLUSION 
 
This study shows that capsaicin has dose-dependent prolongation on the INR. This 
may be due to inhibition of platelet adhesion, or indirectly, due to 
haemoconcentration. This view supports the work of Jaiarj et al. (1998) which 
shows that capsaicin has antithrombotic effects. Unlike the report of Jaiarj et al. 
(1998), however, the present study suggests that the anti-thrombotic effect of 
capsaicin is related to its effects on the common and/or the extrinsic pathway, rather 
than any antiplatelet activity.  Addition of capsicum to meals may achieve the 
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Effects of Capsaicin on cardiovascular function using Lagendorff’s 
heart preparation  
 
SUMMARY:  The present study investigated the effects of capsaicin on the 
myocardial contractility using Lagendorff‟s apparatus. The results showed biphasic 
effects with concentration-dependent increases in the heart rate from a capsaicin 
concentration of 0.05 µg/ml up to a concentration of 0.3 µg/ml (P<0.001), and 
decreases in the mean heart rate from a concentration of 0.3- 1 µg/ml (P< 0.001). 
The slope of the left ventricular diastolic pressure per unit change in time (dp/dt) 
showed a concentration-dependent reduction in the left ventricular contraction when 
treated with capsaicin at a concentration range of 0.05-1 mcg/ml (P < 0.001). Unlike 
earlier studies, the bulk of the evidence from this study showed that capsaicin 
extract may not be the best agent to protect the heart against ischaemia-reperfusion 
injury.  
 
8.1.   INTRODUCTION 
Capsaicin has been in use for over 5000 years by the human race, notably as spices 
(Weil, 1981). Not until recently has research efforts been directed towards its nature 
and physiological actions. Significant progress had been made in the understanding 
of the actions of capsaicin in humans, notably on the central nervous sysem (CNS), 
gasrointestinal tract (GIT), and pain management. The pharmacodynamic effects of 
capsaicin on the cardiovascular system remain elusive. Some actions of capsaicin on 
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the heart were attributed to an interaction with K
+
 channels (Castle, 1992), liberation 
of neuropeptides, most notably calcitonin-gene-related-peptide (CGRP) from the 
vanilloid-sensitive innervation of the heart (De Siqueira, et al., 2006; Franco-
Cereceda et al., 1988; 1991; Ono et al., 1989). The possibility of a direct effect of 
capsaicin on the heart via a cardiac vanilloid receptor (VR), or through interaction 
of vanilloid receptors with purinergic receptors and subsequent release of nitric 
oxide (NO), leading to vasodilatation were considered. Evidence abound in the 
literature that Ca
2+ 
ions are released through 1, 4, 5 inositol phosphatase by the 
release of phospholipase C, or through interaction of the vanilloid receptors with 
cannabinoids.  
This study was designed to investigate the effects of capsaicin on heart rate, cardiac 
contractile force, coronary perfusion, ischaemic-reperfusion effects, with the aim of 
obtaining a better understanding of the effects of capsaicin on the myocardium. 
 
8.2.        METHODS 
 
8.2.1.     ANIMALS 
 
Experiments were performed on male Wistar rats (250-300 g body weight). The rats 
were maintained under standard laboratory conditions of light, temperature, and 
relative humidity. The animals were fed with standard pellet diet and drinking tap 
water ad libitum, and kept in the Biomedical Resource Unit of the University of 
KwaZulu- Natal, Durban. The animals‟ hearts were harvested following passive 
euthanasia subsequent to cervical vertebrae disarticulation. 
 
8.2.2.             MYOCARDIAL STUDIES 
 
Six rats‟ hearts were prepared and treated with 0.05-1 µg/ml of capsaicin extract in 
a 50-ml Lagendorff‟s apparatus. Seven concentrations of capsaicin extract were 
administered, including CFE, 0.05, 0.1, 0.2, 0.4, 0.6, 0.8 and 1.0 µg/ml, 
respectively. The end points measured were changes in the heart rate, coronary 
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perfusion pressure, and the left ventricular contractions, using a constantly perfused 
rat heart in Langendorff‟s apparatus.  
 
Following treatments, the hearts were exposed to 30-min ischaemia followed by 60- 
min reperfusion. The hearts were then treated with 1% triphenyltetrazolium chloride 
(TTC) (Holmbom, et al., 1993); an agent that stains tissues and allows them to 
retain their architecture. Histopathological slides of the hearts were prepared and 
examined for evidence of ischaemia and/or infarction, usng a simple microscope. 
The results were compared with the controls with the help of a Pathologist. 
 
8.3.        RESULTS 
 
The results show a concentration-dependent and significant increase in the heart rate 
from a capsaicin concentration of 0.05 µg/ml to a concentration of 0.3 µg/ml 
(P<0.001). Thereafter, there was a concentration-dependent decrease in the mean 
heart rates from a concentration of 0.3 to a concentration of 1 µg/ml (P< 0.001). 
Statistical calculations were done using Graph Pad Prism 4 software and the 
Microsoft excel.  
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Figure 8.2.  Regression analysis of capsaicin. Effects of escalated concentrations of 





Figure 8.3.  Best line of fit for a slope running from y to x axis showing a drop in 
the heart rate following capsaicin administration. 
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Left ventricular diastolic pressures (in unit time) were computer-generated using the 
ADT PowerLab data acquisition. It showed a concentration-dependent reduction 








Figure 8.4.2.       LVDP/Time curve at 7 min. 
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Figure 8.4.4.       LVDP/Time curve at 19 min. 
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Time 
Figure 8.4.5.     LVDP/Time curve at 21 min. 
The slope of these curves (dp/dt) were computed and analysed. This parameter is a 
measure of the left ventricular contraction. The result obtained shows a 
concentration-dependent reduction in the left ventricular contraction when treated 
with capsaicin at a concentration range of 0.05-1 mcg/ml (P < 0.001). 
 
Figure 8.5a.  Mean changes in rats‟ dp/dt in relation to capsaicin treatments using 
Langendorff‟s apparatus. 






21:50.35 21:50.4 21:50.45 21:50.5 21:50.55 21:50.6 21:50.65 21:50.7 21:50.75 21:50.8 
4/05/2007 3:32:08.359 PM 
LVDP (mmHg) 
 144  
 
Figure 8.5b showing reduction in the CPP with increasing doses of capsaicin 
 
8.3.2.             Effects of Capsaicin on ischaemc-reperfusion injury  
 
                                                                                    
        
      Base                                   Slide 1                   Slide 2    Apex          
 
Figure 8.6.1.    Pathological slides for control rats. 
 
 
          
       Base                          Slice 1                          Slice 2                           Apex                                                                                                          
 
Figure 8.6.2.    Pathological slides for rat 2, showing reduction in the uptake of TTC 
stain by infracted tissue. 
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Figure 8.6.3.    Pathological slides for rat 3- Better uptake in TTC stain shows better 
protected cardiac muscles.  
 
 Figure 8.7.   Degree of myocardial ischaemia and/or infarction at specific sites 
caused by ischaemia-reperfusion injury following 2-hr reperfusion in capsaicin-





Figure 8.8.  Correlation between infarct size of left and right ventricles following 
ischaemic reperfusion injury in capsaicin pretreated rat hearts.  
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8.4.        DISCUSSION 
 
Capsaicin acts on vanilloid receptors, which are groups of receptors that are heat 
sensitive. In the recent past, significant progress has been made in the molecular and 
functional characterization of the sub-family now known as “transient receptor 
potential” including TRP V1 (capsaicin-bound vanilloid receptor), and “transient 
receptor potential melastatin” -TRPM (Fleig and Penner, 2004). TRPM channels are 
involved in several physiological and pathological states in electrically-excitable 
and non-excitable cells. This fact has generated an intense interrogation on possible 
medicinal uses of capsaicin, and in drug discovery.  
 
Available evidence in the literature about the changes in heart rate following 
capsaicin administration is mixed. Majority of reports show an increase in heart rate 
with increasing doses of capsaicin. A positive chronotropic and inotropic effects of 
calcitonin-gene-related-peptide (CGRP) and capsaicin was found in the study 
by Franco-Cereceda and Lundberg (1985).
 
 The investigators suggested that release 
of CGRP from local sensory nerves within the heart underlies the cardio-stimulatory 
response to capsaicin. Injection of capsaicin into area postrema in rats led to 
significant increases in the heart rate, blood pressure and renal sympathetic nerve 
activity (Xue and He, 2000). Using a single capsaicin dose of 0.1uml, Nemeth et al,. 
(2001) noted that the heart rate and coronary perfusion decreased significantly in 
streptozotocin-induced diabetic rats. The question remains as to why capsaicin 
could increase heart rate and blood pressure at a certain time and equally cause 
paradoxical reduction of these variables at other times in the same animals. Chang 
et al., (2000) shed light on the possible hypothesis for these paradoxical effects of 
capsaicin. When used alone at a dose of 100 nmol, capsaicin caused tachycardia due 
to the release of tachykinins. However, capsaicin at the same dose caused 
bradycardia following pre-treatment with CRGP (Chang et al., 2000). It was 
deduced that these capsaicin effects were mediated through the axon reflex which 
stimulated the cholinergic neurons of intrinsic cardiac ganglia. 
Furthermore, application of some capsaicin doses (1, 3,
 
10, 30, 100 and 300 
micrograms) by Quest et al., (1984) to cerebro-ventricular regions of chloralose-
anesthetized cats, the 4
th
 ventricle or the cistern magna, resulted in significant 
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increases in the heart rate and blood pressure. Similar treatment and restriction of 
capsaicin treatments into the fore-brain ventricles failed to elicit any significant 
increase in the heart rate or blood pressure. This observation led the investigators to 
conclude that the area on ventral surface of the medulla is extraordinarily sensitive 




Moreover, Malinowska et al., (2001) observed in their study, that activation of 
vanilloid receptors on sensory vagal nerves elicits rapid bradycardia and 
hypotension (Bezold-Jarisch reflex). Recent in vitro experiments revealed that the 
endogenous cannabinoid ligand, anandamide acts as an agonist at the vanilloid VRI 
receptors. Malinowska et al., (2001) also discovered that intravenous injection of 
anandamide, its stable analogue methanandamide, and the vanilloid receptor agonist 
capsaicin, produced a dose-dependent immediate and short-lasting decrease in heart 
rate and blood pressure in the following rank order of potencies: capsaicin > 
methanandamide > anandamide. Malinowska et al. (2001) concluded that the 
endogenous cannabinoid receptor agonist anandamide, and its stable analogue 
methanandamide, induce reflex bradycardia and hypotension (phase I) by activating 
vanilloid VRI receptor. Whereas the mechanism underlying the brief vasopressor 
effect (phase II) is unknown, the prolonged hypotension (phase III) probably results 
from stimulation of the cannabinoid CB1 receptor.  
In another development, the TRPM ion channel sub-family was found by Fleig and 
Penner (2004) to have a profound effect on the regulation of ion homeostasis by 




 ions entry, and subsequent determination 
of the potential of the cell membrane. Ambdukar (2006) suggested that the Ca
2+ 
signalling microdomains were important platforms for the assembly and regulation 





 homeostasis by capsaicin acting on the vanilloid 
receptors (TRPM sub-family of receptors), the calcitonin-gene-related-peptides, 
vasointestinal pepides (VIPs), and cannabinoid receptors, would explain the 
changing behavioural patterns of capsaicin. Thus, capsaicin could produce sweet 
and bitter, sharp or non-sharp taste, analgesia and hyperalgesia, bradycardia or 
 148  
tachycardia, hypotension or transient increase in blood pressure at cellular, 
molecular, tissue and systemic level. 
A plausible explanation for the dose-dependent positive chronotropic effect of 
capsaicin could be its ability to release calcium. Moreover, release of magnesium 
from cardiomyocytes might contribute to bradycardia, reduction in coronary 
perfusion pressure, and hypotension from reduction in afterload. In the same vein, 
alteration in the electrolytes may lead to arrhythmias.  
In order to retain the architecture of the tissue, triphenyltetrazolium chloride (TTC) 
macroscopic staining was done following ischaemia-reperfusion studies. In 
comparison with the control, the results show evidence of ischaemia and segmental 
infarction with diffuse area of necrosis. The degree of infarction/necrosis varied 
from 10%-100% (P<0.0001). Expectedly, the infarction was worse in both 
ventricles and least in the right atrium and the aorta. 
Results from earlier studies show that capsaicin protects ischaemic hearts from 
ischaemia-reperfusion injury. The bulk of the evidence from this study shows that 
the myocardium was irreversibly damaged after ischaemia-reperfusion, following 
pretreatment with capsaicin. Although incremental doses of capsaicin were used, 
this should rather protect against ischaemia-reperfusion based on „multiple-hit 
theory‟, rather than the contrary. 
On the contrary, the reperfusion period of 60 minutes might be questioned as being 
insufficient. In earlier studies, Schwarz et al.
 
(2000) observed that there was no 
statistical significance between a reperfusion time of 60 and 90 minutes, using 
triphenyltetrazolium chloride (TTC) macroscopic staining of rat hearts in ischaemia-
reperfusion studies.  Furthermore, TTC had been found to provide a distinct 
demarcation between viable myocardium (which stains as red), and the non-viable 
myocardium, staining as pale pink, blue, or reddish-brown (Greve and Saetersdal, 
1991; Figure 2-9). 
In clinical studies, the use of beta-blockers and angiotensin converting-enzyme- 
inhibitors (ACEI) have shown tremendous benefits from reduction in the heart rate, 
thereby improving oxygen demand and supply ratio as in beta-blockers, and 
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reduction of the destructive neurohumoral modeling, following ischaemia by the use 
of ACEI, respectively, (Grolleau-Raoux, 1976; Hearse, et al., 1985; Kroll and 
Knight, 1984; Michael, et al, 1999). In this study, the heart rate reduced 
significantly, but with paradoxical and poor inotropic effects at very low heart rates. 
It could be inferred that capsaicin is able to reduce heart rate, as well as impede 
myocardial performance at high doses. The evidence of arrhythmias, ineffective 
contraction from significant reductions of dp/dt max, poses a challenge to the 
efficacy of high doses of capsaicin in myocardial ischaemia. Capsaicin may have its 
benefits at low doses in ischaemia, probably from a primary release of magnesium, 
followed by a massive release of calcium in ischaemia, causing more damage, and 
lipid peroxidation resulting in deleterious inflammatory response syndrome to 
myocardial ischaemia (Turnstall, et al.,1986; Sun, et al, 1995; White, et al., 1983; 
Yamashita, et al., 1998; Yang, et al., 1996).   
 
8.5.       CONCLUSION 
Capsaicin has a biphasic effect on the cardiovascular system. At low doses, there 
was tachycardia, probably from the release of tachykinin with calcium as the 
secondary messenger. This was followed by a dose-dependent bradycardia at higher 
doses, probably from the release of magnesium ions. Possible evidence of cross-talk 
between capsaicin-activated vanilloid receptors and calcitonin-gene-related-peptides 
system could be inferred. The reduction in myocardial contractility, heart rate and 
coronary perfusion supports a tendency for hypotension, as alluded to by earlier 
workers (Jaiarj et al., 1998). While 33% of the studied hearts had less than 20% 
infarction, further work is needed to establish the role of capsaicin as a cardio-
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CHAPTER 9 
 
CONCLUSION and RECOMMENDATIONS 
 
Summary: This chapter assesses the extent to which the objectives of this study 
were achieved. Furthermore, it considers the inferences that could be drawn from 
the studies and then suggests whether the Null Hypothesis or the Alternative to Null 
Hypothesis is true. In line with the objectives laid out, studies were carried out to 
determine the analgesic, anti-inflammatory, coagulatory, gastrointestinal (GIT) and 
the cardiovascular effects of capsaicin. 
 
9.1.     ANALGESIC EFFECTS OF CAPSAICIN 
 
The analgesic and behavioural effects of capsaicin were examined in mice. The „hot 
plate‟ and the „acetic acid‟ test methods showed in vivo, statistically significant 
analgesic effects. The main side-effect was transient episodes of hyperalgesia 
following intraperitoneal administrations of capsaicin. The capsaicin-induced 
hyperalgesia is consistent with the findings of Baumann (1991). This may be due to 
massive release of Substance P from its vesicles, followed by depletion. 
Consequently, depletion of Substance P results in analgesia. Therefore, it is 
recommended to inform patients of possible hyperalgesia, or to mix topical 
capsaicin cream with lignocaine or any other local anaesthetic, prior to its use. This 
study rejects the Null Hypothesis (i.e., that capsacin has no analgesic effect) as 




9.2.         CAPSAICIN and INFLAMMATION 
 
As earlier indicated, capsaicin has proved very useful in intractable pain of 
inflammatory origin, such as from osteoarthritis, pruritus, psoriasis, rheumatism, 
and complex regional pain syndrome (Winter et al., 1995; Woolf, 1998; Yakish, 
1999; Yoshimura et al., 2000).  This study has shown that capsaicin has anti-
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inflammatory effect of statistical significance comparable to the anti-inflammation 
produced by diclofenac. This is due to inhibition of Substance P. In chronic 
inflammatory conditions, it was found that there is an associated up-regulation of 
Substance P receptors (De AK et al., 1990); Velazquez et al., 2002).  
 
The present study accepts the alternative to Null Hypothesis, and rejects the Null 
hypothesis (i.e., that capsaicin has anti-inflammatory effects). In this sense, 
capsaicin and other vanilloid receptor agonists offer alternative analgesics and anti-
inflammatory agents without the widespread side-effects of non-steroidal 
antinflammatory drugs (NSAIDs) at clinical doses.  
 
9.3.    CAPSAICIN and BLOOD COAGULATION  
The study on blood coagulation showed a dose-dependent increase in 
internationalised normalised ratio (INR), suggesting an increase in bleeding time 
and anticoagulation. This is consistent with the findings of Jaiarj, et al., (1998). But 
unlike the latter, platelet adhesion was not increased. It could be inferred that the 
use of capsaicin or Capsicum could have a thromboprophylactic effect. 
Furthermore, biochemical renal function did not change following chronic 
administration of capsaicin. This observation has not been reported before in the 
literature. As suggested earlier, the use of capsaicin in anticipated clotting problems, 
such as in long flights, could prove beneficial without the side-effects of clinical 
bleeding in the body, renal dysfunction, or GIT erosion as for NSAIDs.  
 
9.4.      CAPSAICIN and CARDIOVASCULAR SYSTEM 
 
In this study, the effects of capsaicin on the heart rate, myocardial contractility, 
blood pressure, coronary perfusion, and coronary ischaemia-reperfusion injury were 
investigated. Earlier, a biphasic effect was reported on both the heart rate and the 
inotropic index (dp/dt).  
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Based on normal physiological function; and the blood pressure formula, reduction 
in coronary perfusion will lead to reduction in stroke volume from reduction in 
aortic root pressure. 
Mean Arterial Pressure (MAP) = Cardiac Output (CO) x Total Peripheral Resistance                                                     
                                                      (TPR),  
This leads to reduction in the blood pressure. Previous studies showed that capsaicin 
leads to vasodilation and hypotension (Jaiarj, et. al., 1998). 
 
The reduction in inotropic index (dp/dt) following administration of capsaicin might 
depict a process of myocardial stunning or hibernation following treatment with 
capsaicin. The extent to which this phenomenal reduction in heart rate and 
contractility protects the heart requires further evaluation. Moreover, the post-
ischaemia/reperfusion triphenyltetrazolium (TTC) stains showed only partial, 
statistically insignificant (p>0.05) myocardial preservation. These observations, 
have not been reported by other workers, and further studies will, therefore, be 
required. 
 
9.5.     SIDE EFFECTS 
 
In this study, the notable side-effects of capsaicin as alluded to previously include 
hyperalgesia and irritation to the eyes up to corneal ulceration. Other side effects 
include sweating from vasodilataion, gastroinestinal erosion, and diarrhoea in high 
concentrations. It is important to re-design other capsaicin-related drugs that will be 
devoid of these side-effects, while preserving the potent analgesia, anti-
inflammatory, anti-coagulatory as well as better cardiovascular profiles of capsaicin. 
Such available analogues include Olvanil (Breneman et al., 1992); Nuvanil (Brand 
et al., 1990), and Civamide, which are more potent than capsaicin, with better side-
effect profiles (Hua et al., 1997). 
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9.6.     DRUG DESIGN 
 
In order to design an acceptable analogue of capsaicin, it is essential to study the 
physico-chemical structure of currently related, agents to capsaicin, and determine 
which side-chain produces the undesirable side-effects, such as hyperalgesia. A re-
designing of capsaicin will then be effected by removing the offending peptide or 
side-chain. In the same vein, nuvanil offers an alternative, more soluble and orally 
administered capsaicin analogue. 
 
9.7.        CONCLUSION 
 
Capsaicin and its analogues constitute a class of agents with potential attributes to 
compete favourably with currently-available analgesic and anti-inflammatory drugs 
(Aasvang, 2009), and keenly compete with anticoagulant-antiplatelets without their 
undesirable side-effects. These potential benefits of capsaicin and its analogues 
might have been well observed ages ago. Capsaicin also showed calminative effects 
on GIT smooth muscles, as well as reduction of heart rate at low doses. This will be 
of benefit in borderline myocardial ischaemia by favouring oxygen supply over 
demand. Its anti-inflammatory effects might show promising effects in 





For now, this method of extraction appears to be the safest and cheapest method 
which can achieve up to 97-98% capsaicin as confirmed by Nuclear Magnetic 
Resonance. Further work has to be done to prove whether or not it is on a 
commercial scale. Chromatography will remain the best option.  
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NEUROPHARMACOLOGICAL AND ANTINFLAMMATORY STUDIES 
 
The temperature of the analgesiometer needs standard control at 40 
o
C.  It is also 
essential to standardise the period of the day during which the studies are carried out 
in order to reduce the effects of diurnal variation on the physiology of the animals.  
 
CAPSAICIN and MUSCLES 
In the light of the results obtained from the present study, it is recommended that 
more elaborate human studies in the use of capsaicin in inflammatory bowel 
disease, colonic cancers, which hitherto had been incurative, be carried out. Also the 
use of homeopathic doses of capsaicin in heart rate control and cardioprotection 
should be investigated.  
 
CAPSAICIN and ANTICOAGULATION 
There is confounding evidence resulting from this study to show that capsaicin has a 
role in anticoagulation pathway. But further questions need to be asked, including 
the direct or indirect effects of capsaicin on platelets, cloting factors and the vessels. 
Further work will have to be done to clear these grey areas. 
 
Since this study was not aimed to compare capsaicin with the new vanilloid 
agonists, further studies are needed to establish if these vanilloid agonists will be 
more suitable analgesics, anti-inflammatory, anticoagulant, cardiac and 
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APPENDIX 1 
Publications from Study 
 
(I) Peer reviewed Journals 
1.  Jolayemi A.T.  (2007) Analgesic effects of capsaicin in witstar rats is 
superior to morphine or diclofenac. Regional Anaesthesia and Pain 
Medicine; 32 (5):324-324. 
2.  Jolayemi A.T.  (2008) Cross-talk between the vanilloid and cholinergic 
receptors in guinea-pig ileum. Is capsaicin a partial cholinergic agonist? 
Anaesthesia and Intensive Care; 36 (4):596-596. 
 
(II) Abstracts and Posters to International Congresses 
Jolayemi A. T. Posters and Abstracts to World Congress of 
Anaesthesia (Feb 29-March 02 2007) 
Pain 
 
Anti-inflammatory effects of capsaicin in Witstar rats-a need for review of 
definition of non steroidal, anti-inflammatory agents 
 
Adebayo T Jolayemi  
 
Department of Anaesthesia, Portland Hospital Victoria State Australia 
 
The anti-inflammatory property of Capsaicin (CPF) and Capsicum frutescens Linn. 
[Solanaceae] aqueous fruit extract (CFE) in rabbits. 
 
Sixty rats 250-300 g were divided into 4 groups. Group A was the control (2 ml of 
0.9 % saline) and group B consisted of 10 rats that received i.p. diclofenac (100 
mg/kg) as the positive control. Pre-procedural general anaesthesia was established 
using .25 ml each of hypnoval (midazolam) and anaket (ketamine) i.m. followed by 
baseline measurements of the circumference of both the right and left feet. 
Inflammation was induced in rats‟ hind paw following sub-plantar injection of 
albumin with 0.5-ml/kg fresh egg albumin.  The circumference of the right fore paw 
was repeatedly measured in time intervals of ½, 1, 2, 4, and 12 hours respectively. 
The blood levels of C reactive protein and Cortisol were also measured. Data 
obtained were pooled and analysed using repeated ANOVA, in a general linear 
model with the CPSS software. 
 
Compared to the diclofenac (DIC) group, the degree of inhibition of paw oedema by 
ethyl acetate extract of Capsicum frutescens Linn. [Solanaceae] and synthetic 
capsaicin (Fluka-biotechnika) was statistically significant (P<0.05>0.0001). The 
 163  
reduction of morning corticosterone levels in the extract or capsaicin pre-treated 
compared to the control animals was statistically significant (p< 0.015).   The C -
reactive protein levels were significantly 10 times higher in the treated samples 
showing an immune response to the phlogistic agents. 
 
Capsaicin in this study shows an anti-inflammatory property reaching a peak level 
at 4 hours following administration. 
 
 1. Capsaicin study group. (1999). Treatment of painful diabetic neuropathy with 
topical capsaicin. A multi-centre, double blind, vehicle-controlled study. 
Archives of Internal Medicine, 151:2225-2229. 
 2. Carpenter S E, Lynn B. (1981) Vascular and sensory responses of human 







Cardiovascular effects of Capsaicin Laggendorffs rat heart models 
 
Adebayo T Jolayemi 
 
Department of Anaesthesia; Portland Hospital; Victoria Australia 
 
The aim of this study is to investigate the effects of capsaicin on the heart rate and 
myocardial contractility and the coronary perfusion. 
 
Six rat hearts were prepared and treated using a 50 ml Laggendorfs Apparatus. 
Seven doses (0.05, 0.1, 0.2, 0.4, 0.6, 0.8 and 1.0 mcg/ml) were administered 
respectively. 
 
The results show a dose-dependent increase in the heart rate from a dose of 0.05 
mcg/ml up to a dose of 0.3mcg/ml CAPs at P<0.001, (probably from the release of 
tachykinins with Calcium as the secondary messenger). This was followed by a 
dose-dependent bradycardia at higher doses from a dose of 0.3- 1 mcg/ml at P< 
0.001., probably from the release of Magnesium ions. Possible evidence of cross-
talk between Capsaicin-activated vanilloid receptors and Calcitonin related gene 
peptides system could be inferred. The (dp/dt) were computed and analysed.  The 
result shows a dose dependent reduction in the left ventricular contraction within a 
dose range of 0.05-1 mcg/ml at P < 0.001.The coronary perfusion pressure dropped 
by 67 % from a non-treated to a dose of 0.05mcg/ml. Thereafter the CPP dropped 
inconsistently by 4-8 % between each dose treatments from 0.1-1 mcg/ml.  This 
may infer a tendency for coronary dilatation and consequently on the mean arterial 
blood pressure.    Statistical analysis was done using Graph prism pad software and 
the Microsoft excel. 
 
Capsaicin had shown biphasic effects on the heart rate.  The dose dependent 
reduction in the contractility, heart rate and the coronary perfusion supports a 
tendency for hypotension as alluded to by earlier workers. 
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1. MALINOWSKA B., KWOLEK G. & GOTHERT M. (2001) Anandamide and 
methanandamide induce both vanilloid VR1- and cannabinoid CB1 receptor-
mediated changes in heart rate and blood pressure in anaesthetized rats. Nauyn-




The effects of Capsaicin on coagualation and renal function 
 
Adebayo T Jolayemi 
 
Department of Anaesthesia,  Portland City,  Victoria State Australia 
 
The aim of this study to investigate the effects of capsaicin and Capsicum frutescens 
LINN. [SOLANACEAE] aqueous fruit extract of South African origin on 
coagulation and renal functionis in Witstar rats. 
 
Experimental design was a double-blind,  placebo-controlled,  parallel study. 
Witstar rats weighing 250–300 g were divided into two groups A (n=12) and B. 
Group B consisted of 3 treatment groups of 12 animals per group. They had similar 
demographics and kept under standard laboratory care.  The animals received 2.5,  
5.0,  or 10.0 mg/kg i.p.i respectively. Following treatment,  1.5-2 cc blood was 
collected by intracardiac puncture following deep ether anaesthesia. The blood 
specimen were analysed for serum urea,  creatinine,  platelets,  as well as the INR 
(internationalised normalised ratio). 
 
The result shows dose-dependent increase in INR in the groups compared to the 
control. There mean INR of 1±0.1,  1.4±0.1 and 2.0±0.3 respectively for the 
treatment groups of 2.5,  5.0 and 10 mg/kg was statistically significant (P<0.05).  
The platelets count,  serum urea and creatinine levels were essentially normal.    
Figure1: shows dose-dependent increase in INR from 5-10 mg/kg i.p.i.capsaicin.  
This study shows that capsaicin has dose-dependent effects on the INR and not on 
the platelets. Unlike the earlier report by Jaiarj et. al. (1998) which shows that 
capsaicin has antithrombolic effects,  this study shows that the anti thrombotic effect 
of capsaicin is related to its effects on the common or the extrinsic pathway rather 
than any antiplatelet activity. 
 
In clinical doses, Capsaicin has antithrombotic but no nephrotoxic effects. 
 
Jaiarj P,  Saichompoo S,  Wongkrajang Y,  Vongswan N,  Peungvicha P, 
Jiratchariyakul W    (1998) Cardiovascular  actions of capsaicinoids extract from   
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Vascular anaesthesia 
 
Capsaicin effects on myocardial ischaemic reperfusion in Witstar rat using 
Laggendorff’s heart model.I 
 
Adebayo T Jolayemi  
 
Department of Anaesthesia, Portland Hospital, Victoria, Australia 
 
The aim of the study is to investigate the effects of capsaicin on myocardial 
ischaemic reperfusion injury 
 
Six rat hearts were prepared and treated using 0.05-1 mcg/ml in a 50 ml 
Laggendorfs Apparatus. The ECG,  heart rate,  coronary perfusion and the dp/dt 
were monitored during the treatments. Following treatments with 0.05,  0.1,  0.2,  
0.4,  0.6,  0.8 and 1.0 mcg/ml Capsaicin,  the hearts were exposed to 30 min 
ischaemia followed by 60 min reperfusion. The hearts were then treated with 1% 
triphenyltetrazolium chloride (TTC). Histopathological slides of the heart were 
prepared and examined for evidence of ischaemia and or infarction. The results 
were compared with the control. 
 
The result shows an infarction rate of between 10-100% in the sections. The 
ventricles were more affected with ischaemia-infarction compared to the atria,  base 
or the apex of the heart.In 33 % of the studied heart sections,  the degree of global 
infarction was less than 20 %. The infarction of the ventricles was 95-100% in 50% 
of the slides. The correlation between right and left ventricular reperfusion injury 
was 1 at p< 0.0001. 
 
Although certain areas of the heart were spared of myocardial ischaemic-
reperfusion injury,  further work is needed to establish the role of capsaicin as a 
cardio-protective agent in ischaemic-reperfusion injury. 
 
Xue BJ,  He RR (2000) Changes in heart rate,  blood pressure and renal sympathetic 
nervous system activity induced by microinjection of capsaicin into area 
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(III) Publications submitted to ISI-recognized or SAPSE-rated journals  
 
Central and peripheral analgesic effects of Capsicum frutescens LINN. 
[SOLANACEAE] aqueous fruit extract and capsaicin in mice is comparable to 
analgesia by Morphine and superior to analgesia by Diclofenac.  
 
A. T.  Jolayemia*  J. A.  O.  Ojewoleb  
 
Anti-inflammatory effects of Capsicum frutescens Linn [Solanaceae] aqueous fruit 
extract in rats 
 
A. T.  Jolayemia*   J. A.  O.  Ojewoleb  
 
Capsaicin, its potential medicinal uses, and side effects 
 
A. T.  Jolayemi
a





The effects of capsaicin on coagulation  
A. T.  Jolayemi
a





Capsaicin effects on myocardial ischaemic reperfusion injury in Wistar rat using 
Laggendorffs heart model 
 
A. T.  Jolayemi
a





Effects of capsaicn on the cardiovascular function in isolated rat hearts using 
Laggendorff‟s heart preparation  
A. T.  Jolayemi
a





Peri operative uses of capsaicin  
A. T.  Jolayemi
a





Pharmacological effects of capsaicin on gastrointestinal smooth muscles  
A. T.  Jolayemi
a
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Figure A. 5. Hot Plate Analgesiometer  
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Figure A. 6. Ugo-Baseille Twin Chamber with and without mounted forced 





Figure A. 7. Gemini 7070 Recorder in action  
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Figure A. 10. STH Pump Controller 















Figure A. 11. Atrial and Ventricular Pressure Monitor and Transducer. 
 
 









Figure A. 13. Powerlab Chart 
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Appendix III 
Dissected Animals 
              
Figure A.15. Guinea-pig.               Figure A.16.    Day-old chick 
                                          
Figure A.17. Dissected guinea-pig intestine                 Figure A.18. Dissected rabbit  
 
Figure A. 19. Rat dissected to harvest both the heart and intestine 
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Appendix IV 
Experimental Set-ups 
Set-up for GIT Experiments 
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Isolated Heart Muscle Experiments 
 





Figure A. 22. Showing some histology slides of TTC stained reperfused rats heart 
muscles 
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Appendix V-  Experimental Data (Mean values shown in n=10) 
Table A.5.1a. Concentration-response of ACh (µg/ml) with and without fixed 
doses of capsaicin in chick oesophagus. 
Dose ACh ACh 
ACh + 20 µg/ml 
CPF ACh + 40 µg/ml CPF 
5 3 2 1 
10 9 3 1 
20 26 8 2 
40 33 15 8 
60 42 20 12 
80 54 30 14 
160 70 35 16 
    
 
Table A.5.1b. % maximal contraction of chick oesophagus to ACh (µg/ml) with and 
without fixed doses of CPF. 
Dose ACh ACh ACh + 20 µg/ml CPF ACh + 40 µg/ml CPF 
5 4.5 3 1 
10 12.5 4.5 2 
20 30 15 8 
40 48 30 26 
60 60 48 45 
80 80 55 35 
160 100 50 20 
 
Table A.5.2a. Concentration-response of ACh (µg/ml) with and without fixed doses 
of CPF in isolated rabbit doudenum. 
Dose ACh ACh ACh + 20 µg/ml CPF ACh + 40 µg/ml CPF 
5 0 0 0 
10 10 3 1 
20 22 7 3 
40 34 11 4.5 
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60 40 12 5 
80 53 13 7 
160 65 18 12 
 
Table A.5.2b. % maximal contraction of rabbit duodenum to ACh (µg/ml) with and 
without fixed doses of CPF. 
 
Dose ACh ACh 
ACh + 20 µg/ml 
CPF ACh + 40 µg/ml CPF 
5 0 0 0 
10 15 5 2 
20 34 11 5 
40 53 17 7 
60 63 18.5 8 
80 82 20 11 
160 100 27 18.5 
 
Table A.5.3a. Concentration-response of ACh (µg/ml) with and without fixed doses 
of CPF in isolated guinea-pig ileum. 
Dose ACh ACh alone ACh + 20 µg/ml CPF 
ACh + 40 µg/ml 
CPF 
5 0 0 0 
10 2 1.2 2 
20 8 4 2 
40 20 12 5 
60 35 14 14 
80 58 29 24 
160 72 50 24 
 
Table A.5.3b. % maximal contraction of isolated guinea-pig ileum to ACh (µg/ml) 
with and without fixed doses of CPF. 
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Dose ACh ACh  
ACh + 20 µg/ml 
CPF Ach + 40 µg/ml CPF 
5 0 0 0  
10 3 2 2  
20 11 6 3  
40 28 17 7  
60 49 19 19  
80 81 40 33  





Table A.5.4. Concentration-response of capsaicin (CPF) (µg/ml) with or without 
fixed doses of Atropine (ATR) and the percentage inhibition of contraction in 
isolated guinea-pig ileum.  
Dose CPF CPF + ATR CPF + ATR %age inhibition 
5 0 0 0 
10 6 1.5 75 
20 7 2.5 70 
40 8 3 62.5 
60 10.5 4 58 
80 25 22 12 
 
Table A.5.5. Concentration-response of capsaicin (CPF) (µg/ml) with or without 
fixed doses of ondasetron in isolated guinea-pig ileum shows no predictable 
interaction . 
Dose CPF CPF + OND 
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5 1 20 
10 5 1 
20 5 4 
40 8 6 





Table A.5.6. Mean heart rate response to six treatments of CPF 
(0.05-1µg/ml) 
 
Control T1 T2 T3 T4 T5 T6 
166 162 448 305 286 116 70 
132 137 373 405 188 36 50 
115 305 295 444 96 70 11 
126 125 113 77 96 23 10 
135 182 307 308 167 61 35 
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Figure A.VI.1. Nuclear Magnetic Resonance Identification of capsaicin- courtesy of 
Prof. Francis O. Shode  and Department of Organic Chemistry UKZN/2005. 
 
 





















Appendix VI I 
 




SI Units for Clinical Data  (as advised by JAMA Journal of American Medical 
Association to Authors). 
The following table provides factors for converting conventional units to SI units 
for selected clinical data. Source:  
Conversion: to convert from the conventional unit to the SI unit, multiply by the 











Acetaminophen µg/mL 6.62 µmol/L 
Acetoacetic acid mg/dL 0.098 mmol/L 
Acetone mg/dL 0.172 mmol/L 
Acid phosphatase units/L 1.0 U/L 
Alanine mg/dL 112.2 µmol/L 
Alanine aminotransferase (ALT) units/L 1.0 U/L 
Albumin g/dL 10 g/L 
Alcohol dehydrogenase units/L 1.0 U/L 
Aldolase units/L 1.0 U/L 
Aldosterone ng/dL 0.0277 nmol/L 
Alkaline phosphatase units/L 1.0 U/L 
Aluminum ng/mL 0.0371 µmol/L 
Aminobutyric acid mg/dL 97 µmol/L 
Amitriptyline ng/mL 3.61 nmol/L 
Ammonia (as NH3) µg/dL 0.587 µmol/L 
Amylase units/L 1.0 U/L 
Androstenedione ng/dL 0.0349 nmol/L 
Angiotensin I pg/mL 0.772 pmol/L 
Angiotensin II pg/mL 0.957 pmol/L 
Anion gap mEq/L 1.0 mmol/L 
Antidiuretic hormone pg/mL 0.923 pmol/L 
Antithrombin III mg/dL 10 mg/L 
alpha1-Antitrypsin mg/dL 0.184 µmol/L 
Apolipoprotein A mg/dL 0.01 g/L 
Apolipoprotein B mg/dL 0.01 g/L 
Arginine mg/dL 57.4 µmol/L 
Asparagine mg/dL 75.7 µmol/L 
Aspartate aminotransferase (AST) units/L 1.0 U/L 
Bicarbonate mEq/L 1.0 mmol/L 
Bilirubin mg/dL 17.1 µmol/L 
Blood gases (arterial)       
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     Paco2 mm Hg 1.0 mm Hg 
     pH pH units 1.0 pH units 
     Pao2 mm Hg 1.0 mm Hg 
Bromide mg/dL 0.125 mmol/L 
C-peptide ng/mL 0.333 nmol/L 
C1 esterase inhibitor mg/dL 10 mg/L 
C3 complement mg/dL 0.01 g/L 
C4 complement mg/dL 0.01 g/L 
Calcitonin pg/mL 1.0 ng/L 
Calcium mg/dL 0.25 mmol/L 
  mEq/L 0.50 mmol/L 
Carbon dioxide mEq/L 1.0 mmoI/L 
Carboxyhemoglobin % of  
hemoglobin 
saturation 
0.01 Proportion of  
hemoglobin saturation 
Carotene µg/dL 0.0186 µmol/L 
Ceruloplasmin mg/dL 10 mg/L 
Chloride mEq/L 1.0 mmol/L 
Cholesterol mg/dL 0.0259 mmol/L 
Citrate mg/dL 52.05 µmol/L 
Copper µg/dL 0.157 µmoI/L 
Coproporphyrins (urine) µg/24 hr 1.527 nmol/d 
Corticotropin (ACTH) pg/mL 0.22 pmol/L 
Cortisol µg/dL 27.59 nmol/L 
Cotinine ng/mL 5.68 nmol/L 
Creatine mg/dL 76.26 µmol/L 
Creatine kinase (CK) units/L 1.0 U/L 
Creatinine mg/dL 88.4 µmol/L 
Creatinine clearance mL/min 0.0167 mL/s 
Cyanide mg/L 23.24 µmol/L 
Dehydroepiandrosterone (DHEA) ng/mL 3.47 nmol/L 
Desipramine ng/mL 3.75 nmol/L 
Diazepam µg/mL 3.512 µmol/L 
Digoxin ng/mL 1.281 nmol/L 
Epinephrine pg/mL 5.46 pmol/L 
Erythrocyte sedimentation rate mm/h 1.0 mm/h 
Estradiol pg/mL 3.671 pmol/L 
Estriol ng/mL 3.467 nmol/L 
Estrone ng/dL 37 pmoI/L 
Ethanol (ethyl alcohol) mg/dL 0.217 mmol/L 
Ethylene glycol mg/L 16.11 µmol/L 
Ferritin ng/mL 2.247 pmol/L 
alpha -Fetoprotein ng/mL 1.0 µg/L 
Fibrinogen mg/dL 0.0294 µmol/L 
Fluoride µg/mL 52.6 µmol/L 
Folate ng/mL 2.266 nmol/L 
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Follicle-stimulating hormone mIU/mL 1.0 IU/L 
Fructose mg/dL 55.5 µmol/L 
Galactose mg/dL 55.506 µmol/L 
Glucagon pg/mL 1.0 ng/L 
Glucose mg/dL 0.0555 mmol/L 
Glutamine mg/dL 68.42 µmol/L 
gamma -Glutamyltransferase (GGT) units/L 1.0 U/L 
Glycated hemoglobin (glycosylated  
hemoglobin A1, A1C) 
% of total  
hemoglobin 
0.01 Proportion of total  
hemoglobin 
Glycerol (free) mg/dL 108.59 µmol/L 
Glycine mg/dL 133.3 µmol/L 
Haptoglobin mg/dL 0.10 µmol/L 
Hematocrit % 0.01 Proportion  
of 1.0 






High-density lipoprotein cholesterol (HDL-
C) 
mg/dL 0.0259 mmol/L 
Histidine mg/dL 64.45 µmol/L 
Homocysteine (total) mg/L 7.397 µmol/L 
Human chorionic gonadotropin (HCG) mlU/mL 1.0 IU/L 
Hydroxybutyric acid mg/dL 96.05 µmol/L 
Hydroxyproline mg/dL 76.3 µmol/L 
Immunoglobulin A (IgA) mg/dL 0.01 g/L 
Immunoglobulin D (IgD) mg/dL 10 mg/L 
Immunoglobulin E (IgE) mg/dL 10 mg/L 
Immunoglobulin G (IgG) mg/dL 0.01 g/L 
Immunoglobulin M (IgM) mg/dL 0.01 g/L 
Insulin µIU/mL 6.945 pmol/L 
Iron, total µg/dL 0.179 µmol/L 
Iron binding capacity, total µg/dL 0.179 µmol/L 
lsoleucine mg/dL 76.24 µmol/L 
lsopropanol mg/L 0.0166 mmol/L 
Lactate (lactic acid) mg/dL 0.111 mmol/L 
Lactate dehydrogenase units/L 1 U/L 
Lactate dehydrogenase  
isoenzymes (LD1-LD5) 
% 0.01 Proportion of 1.0 
Lead µg/dL 0.0483 µmol/L 
Leucine mg/dL 76.237 µmol/L 
Lipase units/L 1.0 U/L 
Lipids (total) mg/dL 0.01 g/L 
Lipoprotein (a) mg/dL 0.0357 µmol/L 
Lithium mEq/L 1.0 mmol/L 
Low-density lipoprotein  
cholesterol (LDL-C) 
mg/dL 0.0259 mmol/L 
Luteinizing hormone (LH, leutropin) IU/L 1.0 lU/L 
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Lysine mg/dL 68.5 µmol/L 
Magnesium mg/dL 0.411 mmol/L 
  mEq/L 0.50 mmol/L 
Manganese ng/mL 18.2 nmol/L 
Methanol mg/L 0.0312 mmol/L 
Methemoglobin % of total  
hemoglobin 
0.01 Proportion of total  
hemoglobin 
Methionine mg/dL 67.02 µmol/L 
Myoglobin µg/L 0.0571 nmol/L 
Nicotine mg/L 6.164 µmol/L 
Nitrogen, nonprotein mg/dL 0.714 mmol/L 
Norepinephrine pg/mL 0.00591 nmol/L 
Ornithine mg/dL 75.67 µmol/L 
Osmolality mOsm/kg 1.0 mmoI/kg 
Osteocalcin µg/L 0.171 nmol/L 
Oxalate mg/L 11.1 µmol/L 
Parathyroid hormone pg/mL 1.0 ng/L 
Phenobarbital mg/L 4.31 µmol/L 
Phenylalanine mg/dL 60.54 µmol/L 
Phenytoin µg/mL 3.96 µmoI/L 
Phosphorus mg/dL 0.323 mmol/L 
Plasminogen mg/dL 0.113 µmol/L 
  % 0.01 Proportion of 1.0 
Plasminogen activator inhibitor mIU/mL 1.0 IU/L 
Platelets (thrombocytes) x 103/µL 1.0 x 109/L 
Potassium mEq/L 1.0 mmoI/L 
Pregnanediol (urine) mg/24h 3.12 µmoI/d 
Pregnanetriol (urine) mg/24 h 2.97 µmol/d 
Progesterone ng/mL 3.18 nmol/L 
Prolactin µg/L 43.478 pmol 
Proline mg/dL 86.86 µmol/L 
Prostate-specific antigen ng/mL 1.0 µg/L 
Protein, total g/dL 10.0 g/L 
Prothrombin g/L 13.889 µmol/L 
Prothrombin time (protime, PT) s 1.0 s 
Protoporphyrin, erythrocyte µg/dL 0.01777 µmol/L 
Pyruvate mg/dL 113.6 µmoI/L 
Quinidine µg/mL 3.08 µmol/L 
Red blood cell count x 106/µL 1.0 x 1012/L 
Renin pg/mL 0.0237 pmol/L 
Reticulocyte count % of RBCs 0.01 Proportion  
of 1.0 
Salicylate mg/L 0.00724 mmol/L 
Serine mg/dL 95.2 µmol/L 
Serotonin (5-hydroxytryptamine) ng/mL 0.00568 µmol/L 
Sodium mEq/L 1.0 mmol/L 
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Somatostatin pg/mL 0.611 pmol/L 
Taurine mg/dL 79.91 µmol/L 
Testosterone ng/dL 0.0347 nmol/L 
Theophylline µg/mL 5.55 µmol/L 
Thiocyanate mg/L 17.2 µmol/L 
Threonine mg/dL 83.95 µmol/L 
Thyroglobulin ng/mL 1.0 µg/L 
Thyrotropin (thyroid-stimulating 
hormone, TSH) 
mIU/L 1.0 mIU/L 
Thyroxine, free (T4) ng/dL 12.87 pmol/L 
Thyroxine, total (T4) µg/dL 12.87 nmol/L 
Transferrin mg/dL 0.01 g/L 
Triglycerides mg/dL 0.0113 mmol/L 
Triiodothyronine       
     Free (T3) pg/dL 0.0154 pmol/L 
     Resin uptake % 0.01 Proportion of 1.0 
     Total (T3) ng/dL 0.0154 nmol/L 
Troponin I (cardiac) ng/mL 1.0 µg/L 
Troponin T (cardiac) ng/mL 1.0 µg/L 
Tryptophan mg/dL 48.97 µmol/L 
Tyrosine mg/dL 55.19 µmol/L 
Urea nitrogen mg/dL 0.357 mmol/L 
Uric acid mg/dL 59.48 µmol/L 
Valine mg/dL 85.5 µmol/L 
Vasoactive intestinal 
polypeptide 
pg/mL 1.0 ng/L 
Vitamin A (retinol) µg/dL 0.0349 µmoI/L 
Vitamin B6 (pyridoxine) ng/mL 4.046 nmol/L 
Vitamin B12 (cyanocobalamin) pg/mL 0.738 pmol/L 
Vitamin C (ascorbic acid) mg/dL 56.78 µmol/L 
Vitamin D       
    1,25-Dihydroxyvitamin D pg/mL 2.6 pmol/L 
    25-Hydroxyvitamin D ng/mL 2.496 nmol/L 
Vitamin E mg/dL 23.22 µmoI/L 
Vitamin K ng/mL 2.22 nmol/L 
Warfarin µg/mL 3.247 µmol/L 
White blood cell count x 103/µL 1.0 x 109/L 
White blood cell differential 
count (number fraction) 
% 0.01 Proportion of 1.0 
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